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Molecular Determinants of Residual Disease in Ovarian Cancer 
Kshipra M. Gharpure 
Advisory Professor: Anil K. Sood, M.D. 
The standard treatment for high grade serous ovarian cancer is primary cytoreductive 
surgery followed by adjuvant chemotherapy. Residual disease followed by surgery is 
associated with adverse overall and progression-free survival as well as poor 
response to adjuvant chemotherapy. Accurate identification of patients at high risk of 
residual disease will help avoid unnecessary surgeries and help in triaging these 
patients to neoadjuvant chemotherapy prior to interval surgical debulking. In this 
study, we address this clinical issue by identifying and validating molecular biomarkers 
that can predict the likelihood of residual disease in ovarian cancer patients. Using 
publically available databases and microarray datasets, we identify FABP4 and 
ADH1B as markers of residual disease since the high expression of these genes in 
tumor samples is directly associated with the incidence of residual disease. We then 
investigate the underlying biology of residual disease and further demonstrate that 
FABP4 is functionally responsible for aggressive phenotype of ovarian cancer cells 
that lead to residual disease in cancer patients. Using sophisticated bioinformatics 
techniques, several in vitro and in vivo experiments and analysis of patient samples, 
we explored upstream regulation of FABP4 and identified miR-409-3p as a key 
regulator of FABP4 expression. We further discover hypoxia as a main tumor micro-
environmental factor regulating miR-409-3p and FABP4 in ovarian cancer. Using 
RPPA and DESI-MS imaging techniques, we explore the downstream pathways of 
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FABP4 and discovered that FABP4 regulates several pathways associated with 
metastasis as well as it affects several metabolites in ovarian cancer cells. 
Collectively, our study provides the mechanistic understanding of residual disease 
biology and identifies miR-409-3p and FABP4 as potential therapeutic targets for 
ovarian cancer treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
Table of Contents 
Approvals___________________________________________________ i 
Title _______________________________________________________ ii 
Dedication __________________________________________________ iii 
Abstract  ___________________________________________________ iv 
Table of Contents ____________________________________________ vi 
List of Figures _______________________________________________ vii 
List of Tables _______________________________________________ ix 
Chapter 1: Introduction ________________________________________ 1 
Chapter 2: Material and Methods ________________________________ 22 
Chapter 3: Molecular biomarkers for prediction of residual disease in 
ovarian cancer ______________________________________________ 
 
40 
Chapter 4: Effects of FABP4 on tumor progression __________________ 53 
Chapter 5: Upstream regulation of FABP4 _________________________ 65 
Chapter 6: Tumor micro-environmental factors regulating FABP4 and miR-
409-3p ____________________________________________________ 
 
81 
Chapter 7: Downstream effects of FABP4 in cancer cells _____________ 86 
Chapter 8: FABP4 as a predictor of residual disease in uterine cancer ___ 117 
Chapter 9: Therapeutic options to target FABP4 in patients ____________ 119 
Chapter 10: Discussion _______________________________________ 121 
Bibliography ________________________________________________ 133 
Vita _______________________________________________________ 159 
 
vii 
 
List of Figures 
Figure 1: A schema for patients treated on the Anderson Algorithm_________ 9 
Figure 2: Functions of FABP in cells ________________________________ 11 
Figure 3: Role of FABP4 in lipid metabolism and inflammation ____________ 12 
Figure 4: Functions of circulating FABP4 ____________________________ 13 
Figure 5: DESI-MS methodology ___________________________________ 16 
Figure 6: Example of DESI-MS images and comparison with H&E _________ 18 
Figure 7: Overall survival for ovarian cancer patients with R0 or RD _______ 41 
Figure 8: Heatmaps showing expression of top 8 genes that have different 
expression between R0 and RD ___________________________________ 
 
45 
Figure 9: Dot and density plots for FABP4 and ADH1B __________________ 46 
Figure 10: Plots of FABP4 and ADH1B expression in TCGA and Tothill data 
sets _________________________________________________________ 
 
48 
Figure 11: Density plots of FABP4 and ADH1B in ovarian and omental tissue 
samples _____________________________________________________ 
 
49 
Figure 12: Prediction results for the validation cohort ___________________ 51 
Figure 13: Plots of incidence rate of RD as a function of FABP4 and ADH1B  52 
Figure 14: Effects of FABP4 on tumor progression (in vitro) ______________ 54 
Figure 15: Effects of FABP4 on tumor progression (Ectopic FABP4-in vivo) 57 
Figure 16: Effects of FABP4 on tumor progression (silencing FABP4-in vivo)  59 
Figure 17: Effects of FABP4 on tumor progression (silencing FABP4-in vivo, 
additional model) _______________________________________________ 
 
61 
Figure 18: Modified Fagotti score for the in vivo experiments _____________ 63 
viii 
 
Figure 19: Correlation between copy number and mRNA expression levels of 
FABP4 ______________________________________________________ 
 
65 
Figure 20: Upstream regulation of FABP4- selection of miR-409-3p ________ 67 
Figure 21: Regulation of FABP4 by miR-409-3p _______________________ 73 
Figure 22: Effects of miR-409-3p on tumor progression (in vitro) __________ 76 
Figure 23: Effects of miR-409-3p on tumor progression (in vivo) __________ 78 
Figure 24: Modified Fagotti scores for miR-409-3p in vivo experiment ______ 80 
Figure 25: Effect of tumor micro-environmental factors on the expression of 
FABP4 ______________________________________________________ 
 
82 
Figure 26: Regulation of miR-409-3p and FABP4 by hypoxia ____________ 84 
Figure 27: Pathways regulated by FABP4 in ovarian cancer cells _________ 87 
Figure 28: DESI-MS imaging pictures of in vivo tumor tissues ____________ 107 
Figure 29: Effect of FABP4 expression on overall and progression-free 
survival ______________________________________________________ 
 
115 
Figure 30: FABP4 as a predictor of residual disease in uterine cancer _____ 118 
Figure 31: Effect of tamoxifen on expression and functions of FABP4 ______ 120 
Figure 32: Summary Model _______________________________________ 132 
 
 
  
ix 
 
List of Tables 
Table 1: Scoring schema using laparoscopic predictive index value______ 7 
Table 2: List of siRNA and primers sequences______________________ 39 
Table 3: List of 47 probe sets differentially expressed in RD vs R0______ 42-44 
Table 4: List of 32 miRNAs with MIC score > 0.2 ____________________      68-70 
Table 5: Correlation between FABP4 and hypoxia metagene signature___ 85 
Table 6: List of metabolites differentially expressed in low and high FABP4 
groups____________________________________________________ 
 
90-96 
Table 7: Models correlating metabolic profiles and FABP4 expression 
using DESI-MS imaging_______________________________________ 
 
98 
Table 8: List of metabolites present in ‘High FABP4’ patient samples____ 100-102 
Table 9: List of metabolites present in ‘Low FABP4’ patient samples_____ 102-105 
Table 10: List of metabolites present in ‘High FABP4 (control siRNA)’ mice 
samples___________________________________________________ 
 
108-110 
Table 11: List of metabolites present in ‘Low FABP4 (FABP4 siRNA)’ mice 
samples___________________________________________________ 
 
110- 112 
Table 12: List of metabolites present in both human and mice groups-‘High 
FABP4’ ___________________________________________________ 
 
112-113 
Table 13: List of metabolites present in both human and mice groups-‘Low 
FABP4’____________________________________________________ 
 
113-114 
 
 
1 
 
Chapter 1: Introduction 
1.1 Residual disease in ovarian cancer 
Primary cytoreduction followed by adjuvant chemotherapy is the standard 
mode of treatment for ovarian cancer patients. Residual disease following the primary 
debulking surgery has been associated with worse overall and progression-free 
survival as well as poor response to adjuvant chemotherapy. Historically, surgeries 
resulting in the residual tumor of size 2 cm or more were labeled as suboptimal; 
whereas the one resulting in smaller tumors were regarded as optimal surgeries. The 
goal of the primary debulking was to achieve optimal cytoreduction since the survival 
rate was proven to be inversely proportional to the size of the residual tumor [1].  
There were however differences in the definitions of ‘optimal debulking’. In 
1975, a study of 102 patients of stage 2 and 3 concluded 1.5 cm to be the threshold. 
Surgeries that left the patients with a residual tumor greater than 1.5 cm diameter were 
called ‘suboptimal’ whereas others were called ‘optimal’. The study showed poor 
survival for patients with residual disease diameter greater than 1.5 [1]. Later studies 
by Chi et al. and Hoskins et al. (GOG 97), however concluded that patients with 
residual disease less than 1cm had better survival than the ones with larger tumor 
size [2, 3]. Other studies confirmed these observations and a threshold of 1 cm was 
used to determine whether a surgery was optimal or suboptimal [4, 5]. Advances in 
surgical techniques and postoperative care made aggressive cytoreduction more 
feasible and complete resection of residual disease became achievable. Recent 
studies thus focused on the survival differences between complete resection (no 
residual disease, R0) and any visible residual disease (R0). They noticed that each 
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10% increase in extent of debulking resulted in 5.5% or 2-3 months of increase in 
patient survival [6, 7]. GOG trials 104 and 172 further supported the data and 
concluded that significant survival differences exist between patients with no visible 
residual disease and patients with gross residual disease (< 0.5 cm or 0.5-2 cm) [8, 
9]. Studies since then have identified complete cytoreduction as an independent 
prognostic factor for overall survival with data showing the longest survival (86 
months) for patients with no gross residual disease compared to 37-46 months of 
survival for patients with 0.1-1cm and >1cm RD [10, 11]. An exploratory study of 3126 
patients from 3 randomized trials by duBois et al. was one of the largest studies to 
establish the importance of R0. The study concluded that the patients with R0 had 
significantly better survival than patients with RD and there was no significant survival 
difference between patients with RD 0.1-1cm or greater than 1 cm. The study also 
showed the median recurrence time for patients with R0 was 15.5 months, whereas 
recurrence was shorter for patients with RD 0.1-1cm or greater than 1cm [12].  
Though complete resection is the ultimate goal of the surgeries, it should be 
noted that even highly experienced gynecologic oncology surgeons end up leaving 
residual disease. Studies have shown that approximately two-thirds of the patients 
with advanced-stage ovarian cancer get residual disease after the PDS [13]. This can 
happen due to the presence of numerous, dense nodules that simply can’t be 
removed, distant tumor metastasis, location of tumor near critical organs (e.g., porta 
hepatis), extensive mesenteric involvement etc. Thus, not only surgical skills but tumor 
biology also plays a crucial role in residual disease pathology.  
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1.1.1 Neoadjuvant chemotherapy vs primary debulking 
While complete cytoreduction is potentially achievable at most in 30% of the 
cases using aggressive surgical procedures; not all patients can tolerate such an 
approach. Women with advanced stage disease, bulky tumor, widespread metastasis 
or women who are very weak and sick to undergo any surgery may not be good 
candidates for extreme surgical efforts. Neoadjuvant chemotherapy is thus being 
suggested as an alternative to primary debulking surgery. The idea is to reduce tumor 
burden using neoadjuvant chemotherapy and thus improve the chances of achieving 
R0 at the interval surgery. 
A randomized clinical trial of 718 patients was conducted by EORTC (European 
Organisation for Research and Treatment of Cancer) and NCIC 
(National Cancer Institute of Canada). The patients were randomly assigned to 
primary debulking surgery (PDS) or to neoadjuvant chemotherapy (NACT) followed 
by interval debulking surgery (IDS). Although progression-free survival (PFS) and 
overall survival (OS) were similar in both the groups, the rate of achieving optimal 
cytoreduction was higher (80.6%) in patients after NACT-IDS than in the patients who 
received PDS (41.6%). Furthermore, patients who underwent NACT and IDS had 
improved quality of life as measured by lesser postoperative complications and 
infections compared to the patients who received PDS [14]. Results from another 
multicenter phase 3 clinical trial of patients with advanced stage disease showed that 
NACT resulted in higher chances of optimal debulking with similar OS and PFS. 
Several retrospective studies and meta-analyses have so far suggested that NACT is 
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equivalent to PDS in terms of survival and can be a better treatment option for patients 
in which optimal cytoreduction is not possible following PDS [15-18].  
Although neoadjuvant chemotherapy is a potentially feasible alternative, there 
can be risks of side effects, drug resistance and refractory diseases that are 
associated with NACT. Further studies are thus essential before NACT can be 
included in the standard of care [17]. On the other hand, patients who are very sick or 
have tumor burden that cannot be optimally debulked, benefit little from the aggressive 
surgery. They might in fact suffer from the morbidities associated with such an 
approach. It is therefore extremely important to carefully determine whether a given 
patient will benefit from NACT or PDS.  
 
1.1.2 Predictors of residual disease 
To determine if a patient will or will not have a suboptimal resection or residual 
disease, various predictive tools have been developed and tested. 
Given the importance of CA-125 as a marker for advanced stage ovarian 
cancer, many studies have evaluated the ability of CA-125 as a predictive marker for 
optimal cytoreduction [19-21]. Optimal debulking was achieved in 73% of the cases 
when CA-125 levels were lower than 500 U/ml, conversely when CA-125 levels were 
higher than 500U/ml, only 22% of the cases resulted in optimal cytoreduction [20]. 
Some studies also evaluated the changes in serum CA-125 after NACT and 
concluded that patients with CA-125 levels < 100 U/ml are likely to achieve R0 status 
after IDS than patients with higher CA-125 levels [22]. However, contradicting results 
from additional studies suggested that levels of CA-125 cannot be used as a reliable 
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predictor for suboptimal cytoreduction [23-26]. Another such serum marker (HE4) was 
also evaluated and retrospective analysis indicated HE4 levels of 264pmol/L and 
ascites volume < 500mL can predict optimal cytoreduction with 100% sensitivity and 
89.5% specificity [27]. The studies however lack external validations.  
Computed Tomography (CT) imaging is the most commonly studied modality 
to predict residual disease in patients. Several studies have tried to build prediction 
models based on the CT scans of ovarian tumors. In a retrospective study of 118 
patients, Kim et al. identified extension of omental disease to stomach and spleen, 
and metastasis at inguinal and pelvic lymph nodes observed in CT scans as predictive 
markers for suboptimal cytoreduction in ovarian cancer patients [28]. Another study 
reported CT findings of attachment of the omentum to the spleen and tumor burden 
of greater than 2 cm on the diaphragm, liver surface, or parenchyma, pleura, 
mesentery, gallbladder fossa, or suprarenal para-aortic nodes to be predictors of 
residual disease with a positive predictive value of 67% and negative predictive value 
of 96% [29]. Similar retrospective studies by Bristow et al. and Dowdy et al. reported 
large volume of ascites and CT scan showing peritoneal thickening, omentum 
extensions and mesenteric tumor burden as predictors of suboptimal cytoreduction 
[30, 31]. A prospective, multicenter, non-randomized trial of advanced stage ovarian 
cancer patients was conducted to explore the combination of CA-125 and CT scan as 
a predictive tool for suboptimal primary debulking surgery. Advanced stage, CA-125> 
500U/ml and metastasis at retroperitoneal lymph node, small bowel mesentery, 
superior mesenteric artery, perisplenic area, lesser sac and small bowel thickening 
were found to be indicators of suboptimal surgery.  A predictive model using these 
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criteria had an accuracy of 0.758 [32]. In another retrospective study, Janco et al., 
analyzed data from 279 patients and built a predictive model based on age, Eastern 
Cooperative Oncology Group performance status (ECOG PS), American Society of 
Anesthesiologists (ASA) score, thrombocytosis, CA-125 levels, albumin levels and CT 
images of lymphadenopathy (LP), large-volume ascites, diffuse peritoneal thickening 
(DPT), omental cake, and spleen or liver involvement. ECOG PS, DPT, and LP were 
found to be markers of suboptimal surgery with c index value of 0.685[33]. 
Although studies have indicated that CT-based predictive models of residual 
disease are promising, they have not been extensively validated. Moreover, the 
predictive ability of CT scans depend largely on radiological skills, surgical techniques 
and surgeon’s and radiologist’s view and assessments of the scans [13, 34]. 
Since the previously described predictive models had limited success, 
laparoscopic methods were explored to assess the resectability of tumor burden. A 
pilot study comparing the predictive ability of laparoscopy and laparotomy revealed 
the overall accuracy of laparoscopy in predictive residual disease as 97%. In no cases, 
the prediction of suboptimal disease changed by the laparotomy performed later. Thus 
laparoscopy was proved to be as reliable as laparotomy while avoiding unnecessary 
cytoreduction and morbidity associated with laparotomy [35]. Fagotti et al. then 
developed a quantitative prediction model based on the laparoscopic findings of tumor 
metastasis. Table 1 describes the scoring schema formulated by Fagotti et al. to 
calculate predictive index value (PIV) for each patient [13, 36]. A score of 8 or above 
was said to predict the likelihood of suboptimal cytoreduction. The positive predictive 
value for the technique was 100% whereas the negative predictive value was 70% 
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[36]. This method of a score-based predictions of RD was evaluated by at least two 
other studies- A study by Angioli et al. reported that 96% of the patients predicted to 
have R0 resection, had optimal debulking [37]. Brun et al. reported that the specificity 
and positive predictive values for the Fagotti score were 89% and 89% respectively 
while the sensitivity and negative predictive values were 46% and 44% [38].  
Table 1 A scoring schema developed by Fagotti et al. to calculate predictive index 
value (Taken with permission from the copyright holder, Nick, A.M., R.L. Coleman, 
P.T. Ramirez, and A.K. Sood, A framework for a personalized surgical approach to 
ovarian cancer. Nat Rev Clin Oncol, 2015. 12(4): p. 239-45.) 
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To assess the accuracy of the laparoscopic measurements, Fagotti et al. 
conducted a multicenter, prospective trial (Olympia-MITO13) of 120 patients. Apart 
from mesenteric retraction, all other variables reached an accuracy rate of 80% or 
more thus establishing the reproducibility of laparoscopic scoring [39]. The Fagotti 
score was again used in the SCORPION trial where primary debulking and 
neoadjuvant chemotherapy followed by IDS were compared. Patients with scores 
between 8-12 were randomly triaged to receive either neoadjuvant chemotherapy or 
PDS. The primary results of the trial were promising. The study reported that rates of 
complete debulking (R0) were similar in both the groups and quality of life scores were 
better for the patients who received neoadjuvant chemotherapy [40]. The predictive 
index scoring is also a part of M.D. Anderson algorithm which was developed as a 
part of the women’s cancer moon shot program. Figure 1 explains the algorithm. As a 
part of quality improvement initiative, a laparoscopic assessment is conducted for 
each patient and the scoring is done by two surgeons to ensure an agreement about 
tumor resectability. An additional opinion is considered if necessary. After this careful 
assessment of disease distribution by two or more surgeons, a patient is triaged either 
for PDS or NACT followed by IDS depending upon the scores. Thus PDS is 
recommended for patients only when R0 resection is potentially achievable. Novel 
therapeutic agents are offered to the patients after the laparoscopy and prior to the 
PDS (window of opportunity). Preliminary results have indicated increased rates of 
complete resection (20% pre-implementation versus 84% post-implementation) and 
improved chances of R0 after neoadjuvant chemotherapy (65% pre-implementation 
versus 100% post-implementation) [13].  
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Figure 1 A schema for patients treated on the Anderson algorithm 
(Taken with permission from the copyright holder, Nick, A.M., R.L. Coleman, P.T. 
Ramirez, and A.K. Sood, A framework for a personalized surgical approach to ovarian 
cancer. Nat Rev Clin Oncol, 2015. 12(4): p. 239-45.) 
 
Residual disease could be a result of lack of surgical skills or location of nodules 
near critical organs or it could be because of invasive tumor biology. Considering that 
residual disease could be a consequence of biological characteristics of tumors, we 
hypothesized that tumor tissue based markers might be able to predict the likelihood 
of residual disease with high sensitivity. If a certain numeric threshold is established 
for the gene expression, then this method is essentially free of any subjective 
assessment seen in CT scans etc. Some studies have tried to develop molecular 
predictors for residual disease. They do however have certain limitations. Using 
stringent inclusion, exclusion criteria for tumor samples and validation studies, we 
discovered molecular biomarkers (FABP4 and ADH1B) to predict residual disease in 
ovarian cancer. 
1.2 FABP4 (Fatty acid binding protein 4) and its biological functions 
1.2.1 Role of FABP4 in various cell types 
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The FABP4 gene encodes fatty acid binding protein 4. It belongs to a family of 
fatty acid binding proteins that are intracellular lipid chaperons. They can reversibly 
bind to hydrophobic ligands such as fatty acids, eicosanoids and other lipids. The 
molecular weight of FABPs is 14-15 kDa and they share 20-70% sequence identity 
between different isoforms. Fatty acid binding protein 4 is also knowns as A-FABP4 
or ap2 since it was first detected in adipocytes. Since then studies have shown that 
FABP4 is also present in macrophages, endothelial cells, dendritic cells and tumor 
cells [41-43]. In all these various cell types; FABP4 plays crucial roles in various 
cellular functions.  
As a lipid chaperon, FABPs can transport fatty acids and lipids to various cell 
organelles. For example, it can transport lipids and fatty acids to mitochondria or 
peroxisome for oxidation, to the nucleus for lipid-mediated transcriptional regulation. 
The cells can secrete FABP4 and thus lipids outside the cells as a means of paracrine 
communication or it can store it in cytosol to regulate enzymatic activity. FABP4 can 
also send lipids to endoplasmic reticulum for membrane synthesis and signaling or it 
can transport fatty acids, lipids to lipid droplets for storage [44]. 
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Figure 2 Functions of FABP in the cells [44] 
(Taken with permission from the copyright holder. Furuhashi, M. and G.S. Hotamisligil, 
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. 
Nat Rev Drug Discov, 2008. 7(6): p. 489-503.) 
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Figure 3 Role of FABP4 in lipid metabolism and inflammation[45] 
(Taken with permission from the copyright holder. Hotamisligil, G.S. and D.A. 
Bernlohr, Metabolic functions of FABPs--mechanisms and therapeutic implications. 
Nat Rev Endocrinol, 2015. 11(10): p. 592-605.) 
 
FABP4 is known to be upregulated during differentiation of preadipocytes into 
adipocytes [46] and is known to regulate de novo lipogenesis [47]. It suppresses 
adipose tissue lipogenesis and increases lipolysis. It is also known to regulate 
eicosanoids, JAK2 and CD36 thus influencing various pathways related to 
inflammation. Increased levels of secreted FABP4 have been linked with obesity. 
FABP4 regulated lipid signaling has been known to influence glucose tolerance and 
insulin sensitivity. 
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Figure 4 Functions of circulating FABP4[45] 
(Taken with permission from the copyright holder. Hotamisligil, G.S. and D.A. 
Bernlohr, Metabolic functions of FABPs--mechanisms and therapeutic implications. 
Nat Rev Endocrinol, 2015. 11(10): p. 592-605.) 
 
FABP4 present in lung endothelial cells has been implicated in VEGF-induced 
airway angiogenesis and inflammation. Studies have thus shown that FABP4 plays a 
key role in vascular remodeling of airways and thus pathogenesis of asthma [48].  
FABP4 is also expressed in differentiated and activated macrophages [44]. It 
regulates cholesterol accumulation in macrophages and also modulates inflammatory 
responses. It regulates several cytokines and pro-inflammatory enzymes such as 
tumor necrosis factor (TNF-1α), interleukin 1-β (IL1β), monocyte chemoattractant 
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protein 1 (MCP1), nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2). FABP4 
has also been shown to regulate NF-kB and IKK (inhibitor of kappa kinase) and thus 
controls inflammatory and cytokine responses [49]. FABP4 also regulates foam cell 
formation and thus contributes to atherosclerosis [49, 50].  
1.2.2 Role of FABP4 in cancer progression 
Recent studies have highlighted the importance of FABP4 in tumor 
progression. In HUVEC cells, FABP4 regulates several pathways involving P38, 
eNOS, stem-cell factor (SCF)/c-kit and controls endothelial cell proliferation, migration 
and sprouting. In ovarian cancer, FABP4 has been shown to increase angiogenesis 
thus contributing to tumor progression [43]. In endothelial cells, inhibition of FABP4 
increased reactive oxygen species and decreased angiogenesis. Knockdown of 
FABP4 in vivo using siRNA treatment, reduced proliferation (ki67), increased 
apoptosis (CC3) and reduced number of endothelial vessels (CD31) and thus had 
tumor inhibitory effects [51].   
In ovarian cancer, FABP4 is known to play a key role in the interaction between 
cancer cell and adipocytes. Co-culture of adipocytes and cancer cells resulted in 
FABP4 mediated increased lipid content in cancer cells. Adipocytes thus provided 
lipids and induced β oxidation pathway in cancer cells, therefore promoting tumor 
progression by providing energy to cancer cells. The study further showed that 
knockout mouse model of FABP4 had lesser metastasis than the control mice [52]. In 
oral squamous cell carcinoma, FABP4 is predominantly expressed in tumor tissues 
compared to the non-tumorous tissues. Moreover, knockdown of FABP4 in SCC 
cancer cell line resulted in decreased cell proliferation possibly by inhibition of 
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phosphorylation of MAPK [53]. In breast cancer cells, treatment with exogenous 
FABP4 led to increased cell proliferation by inducing AKT-MAPK signaling cascade. 
Increase in FABP4 also led to an increase in the expression of fatty acid transport 
proteins in these cells which can also leads to increasing proliferation [54].   
Our study focuses on FABP4 specifically present in the ovarian cancer cells 
and how it induces aggressive and infiltrative phenotype in the cells which ultimately 
results in residual disease. 
1.3 Desorption electrospray ionization mass spectrometry 
Since some of the proteins that were significantly altered in our RPPA analysis 
are also known to influence metabolic pathways and most importantly FABP4 is a fatty 
acid binding protein known to be involved in fatty acid oxidation pathways, we decided 
to investigate whether FABP4 affects the metabolic profile of ovarian cancer cell. 
Ovarian cancer metabolomics have been studied previously. Studies revealing 
glutamine dependency of cancer cells, importance of n-acetylaspartate pathway, 
amplification of USP13 or higher expression of fatty acid synthase; have all 
established the importance of metabolic changes occurring in cancer cells[55-58]. 
However, the studies do not provide spatial resolution of the metabolites. Without this 
information, it is difficult to pinpoint the exact compartment of the tumor (cancer cells 
or stroma) where the changes are occurring and hence it is difficult to fully 
comprehend the dynamics of these changes.  Imaging techniques coupled with MS 
spectrometry, not only identify molecules or metabolites in a given sample but also 
provide information about their spatial distribution. DESI-MS imaging is one such 
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technique particularly used to analyze metabolites with low m/z values, such as lipids 
[59].  
DESI-MS imaging has been used to analyze tissue extracts or plants or animal 
tissues [60-64]. Briefly, for the tissue analysis, a section of approximately 5-25 µm 
thickness is used. Then, a spray of solvents is directed onto the sample. When the 
droplets hit the tissue section, the analytes present in that area get dissolved in the 
solvent. A continuous spray of the solvent helps to generate secondary microdroplets 
containing the analytes that are then delivered to the mass spectrometry through an 
extended heated capillary[65]. Tandem MS is then used to identify the analytes. An 
image showing spatial distribution can then be made for each analyte. The most 
commonly used solvent system for DESI-MS imaging is a mixture of water and 
methanol or acetonitrile in  combination with an acid modifier [61]. The composition of 
the solvent used for the analysis is critical since it can affect desorption and ionization 
of the molecules. The polarity of the solvent system also has an impact on the signals 
obtained from the species and can be adjusted to specifically focus on certain species 
[66, 67].  
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Figure 5  DESI-MS imaging methodology [68] 
(Taken with permission form the copyright holder. Takats, Z., J.M. Wiseman, B. 
Gologan, and R.G. Cooks, Mass spectrometry sampling under ambient conditions 
with desorption electrospray ionization. Science, 2004. 306(5695): p. 471-3.) 
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Since the technique does not require any staining or labelling procedures, the 
tissue morphology is maintained during the analysis [65]. This allows the images 
constructed from the MS data, to be directly compared with the H&E images of the 
tissue sections. Thus, it also helps to select the data from specific areas of the tissue 
sections, if needed. Figure 6 shows how DESI-MS images are analyzed along with 
H&E sections to know locations of a metabolite’s signals. 
  
Figure 6 Example of DESI-MS images and comparison with H&E [69] 
(Taken with permission from the copyright holder Zhang, J., W. Yu, S.W. Ryu, J. Lin, 
G. Buentello, R. Tibshirani, J. Suliburk, and L.S. Eberlin, Cardiolipins Are Biomarkers 
of Mitochondria-Rich Thyroid Oncocytic Tumors. Cancer Res, 2016. 76(22): p. 6588-
6597) 
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DESI-MS imaging has been mainly used to identify lipids present in the 
biological specimens. In case of spinal cord injury, it has been used to explore time-
dependent chemical changes in the tissue and associate lipidomic profiles with the 
injury [70]. Sequential analysis of 2D images collected from DESI-MS has been used 
to construct 3D images of a mouse brain thus allowing to associate specific molecular 
moieties with the substructures of brain [71]. Recent studies have focused on using 
DESI-MS imaging as a diagnostic tool to differentiate between normal and cancerous 
tissues. For example, in bladder cancer, a study of patient tissue samples revealed 
that certain fatty acids, glycerophosphoinositols (PI) and glycerophosphoserines (PS) 
are elevated in tumors compared to adjacent normal tissue [72, 73]. DESI-MS analysis 
of prostate cancer tissues was also able to differentiate between cancerous and 
normal sections based on cholesterol sulfate expression [74]. Similar studies in 
glioblastoma, seminoma tissues and ovarian cancer have been conducted [75, 76]. In 
all these studies, DESI-MS imaging was able to provide a visual distinction between 
cancerous lesions and normal tissue section of a given specimen. Current work in the 
field is focused on using DESI-MS for more complex classifications such as tumor 
grading, differentiating between molecular subtypes of a cancer etc. 
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A comprehensive study of the determinants of residual disease is an unmet 
need in the field of ovarian cancer. In this study, we first aimed to identify molecular 
biomarkers that can predict the likelihood of residual disease with high sensitivity and 
selectivity. After discovering FABP4 as a biomarker for residual disease, we studied 
the upstream mechanism that leads to its upregulation in ovarian cancer. We then 
investigated the pathways regulated by FABP4 that eventually lead to residual disease 
in ovarian cancer. 
Specific aims and hypothesis: 
Aim 1: To identify a gene signature that will predict the residual disease status in 
ovarian cancer patients. 
Hypothesis: A gene signature predictive of residual disease status can be identified 
through integrative analysis of patient database 
Rationale: The standard treatment for ovarian cancer is to surgically remove as much 
tumor as possible, followed by chemotherapy. Recent reports suggest that patients 
most likely to benefit from surgery upfront are those with complete resection of disease 
(R0), which is among the strongest predictors of overall survival. The rates of R0 
resection are approximately 30%. Unfortunately, all patients are currently subjected 
to a large incision for surgery when only 30% will have R0 resection and the remaining 
would ideally be treated with neoadjuvant chemotherapy. There are no reliable 
methods (e.g., imaging, biomarkers, etc.) that can accurately predict whether a given 
patient will have R0 resection at surgery. We therefore aim to identify molecular 
predictors of residual disease to allow reliable prediction of those most likely to benefit 
from surgery (i.e., achieve R0 resection). 
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Aim 2: To identify the mechanisms by which FABP4 is up regulated in ovarian cancer 
Hypothesis: Decreased miRNA levels lead to elevated expression of FABP4 in 
ovarian cancer cells. 
Rationale: High expression of FABP4 was found to correlate with high likelihood of 
residual disease. Analysis of TCGA data revealed there is no correlation between 
copy number and high FABP4 expression. After screening various micro-
environmental factors, hypoxia seems to be the dominant factor related to 
upregulation of FABP4 in ovarian cancer cell lines. Through our in silico analysis, we 
discovered several miRNAs predicted to bind to 3’UTR of FABP4. Hence we propose 
that a miRNA is the main regulator of FABP4 in ovarian cancer and is the reason of 
its high expression in high grade serous ovarian tumors.  
 
Aim 3: To determine the biological consequences of increased FABP4 expression on 
ovarian cancer growth and metastasis and investigate the underlying mechanisms. 
Hypothesis: FABP4 promotes ovarian cancer metastasis by regulating key proteins 
and metabolites in cancer cells. 
Rationale: One of the reasons that tumors cannot be resected is that they are widely 
disseminated or they are infiltrated into normal organs. Our preliminary results show 
that ectopic FABP4 promotes migration and invasion of cancer cells and silencing 
FABP4 inhibits these processes. We hence believe that higher expression of FABP4 
makes the cancer cells more infiltrative and metastatic, leading to residual disease.  
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Chapter 2: Methods 
Data for exploratory studies 
For biomarker discovery, we used 2 large publicly available Affymetrix 
microarray datasets involving patients with HGSOCs and providing associated clinical 
information, including residual disease status. The first of these was the ovarian 
cancer cohort from The Cancer Genome Atlas [77]. We downloaded CEL files (level 
1 data) for the ovarian samples (Affymetrix HT HG-U133A arrays, n = 598) on 
September 2, 2012; these represent the TCGA update that was current as of June 24, 
2011 (revision 1007). We downloaded the associated clinical data (n = 576) on 
September 14, 2012. We excluded samples if they were from recurrent tumor, omental 
tumor, or normal tissue. When there were multiple primary tumor samples per patient, 
we retained data from just one sample. We also excluded cases if there was no 
information about residual disease status, if the tumor was not high grade, or if the 
patient received neoadjuvant chemotherapy. The second dataset was from the study 
of Tothill and colleagues [78]. We downloaded CEL files (Affymetrix U133+2 
arrays, n = 285) and clinical data from the Gene Expression Omnibus (GSE9891) on 
September 13, 2012. We excluded cases from this dataset if tumor samples were low 
grade, of low malignant potential, non-serous histology, or non-ovarian or peritoneal 
origin. Cases were also excluded if the patient received neoadjuvant chemotherapy 
or if residual disease status was not provided. Accordingly, biomarker discovery was 
performed using only data from primary tumors of chemotherapy naïve patients with 
HGSOC. 
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For each of the datasets described above, we quantified expression at the 
probeset level with R statistical software (version 2.15.1) using the robust multi-array 
average procedure as implemented in the subroutine justRMA in the R “affy” package 
(version 1.34.0). We only considered probesets common to the array platforms used 
in the first 2 datasets. Except for the 4 samples marked for exclusion by TCGA, our 
sample filtrations described above were performed subsequent to the quantification 
step. 
 
Validation studies 
Following identification of candidate genes having a wide dynamic range and 
with high expression levels associated with high risk of residual disease in exploratory 
analyses, we performed validation studies in an independent cohort. Following 
Institutional Review Board approval, we obtained primary ovarian tumor samples from 
archived surgical material at The University of Texas MD Anderson Cancer Center 
(Houston, TX; n = 84) and the Pacific Ovarian Cancer Research Consortium at the 
Fred Hutchinson Cancer Research Center (Seattle, WA; n = 55). We also included 41 
samples of omental tumor tissue from MD Anderson for comparison. All samples were 
selected from chemotherapy naïve tumors. Information about residual disease status 
in the validation cohort was extracted from patient medical records by clinical 
members of the team and was scored as R0 versus any residual disease. This 
information was kept blinded from all other team members until after predictions were 
made concerning identification of a subset of patients at high risk for residual disease. 
24 
 
These predictions were made on the basis of expression levels of a candidate gene 
of interest relative to 18S, assayed using qRT-PCR. 
 
Exploratory data analyses. 
We used 2-sample t tests to compare expression levels by residual disease 
status (R0 vs. any residual disease) in the TCGA and Tothill datasets, separately. We 
analyzed the resulting collections of nominal P values to identify probesets significant 
at a 10% or 5% false discovery rate (FDR) in each data set separately. We selected 
probesets meeting the specified criterion in both subsets. We produced density plots 
for these probesets, as well as heatmaps using hierarchical clustering, to illustrate 
patterns of expression. We examined the resulting plots to identify probesets with (i) 
wide dynamic range and (ii) high levels of expression associated with particularly high 
incidence of residual disease. We examined similar plots for the selected probesets 
in the Bonome and CCLE datasets to see whether the qualitative expression patterns 
were also observed there. 
 
Selecting a sample size and prediction threshold for the validation study. 
Following identification of genes for which high expression levels were 
associated with high risk of residual disease, we wished to select an a priori decision 
threshold for “calling” a patient in the validation cohort to be at high risk of residual 
disease based on elevated biomarker expression measured by qRT-PCR. Patients 
with expression of a candidate biomarker gene above the selected threshold would 
be in the predicted high-risk group for residual disease. To select a decision threshold, 
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we first computed the positive predictive values (PPV) in the TCGA and Tothill 
datasets at thresholds defined by varying quantiles of biomarker expression. We 
assumed that similar PPVs would apply to the validation cohort and performed 
numerical simulations to determine a decision threshold at which we would be 
maximally powered to detect a difference in incidence of residual disease in the 
validation set. We chose a threshold with an estimated power of at least 80% to detect 
a difference in incidence of residual disease significant at P < 0.05 using a 1-sided 
Fisher exact test. We used similar simulations for our initial sample size computations 
before collecting the validation set. 
 
Statistical assessment of success. 
We constructed a 2 × 2 table showing our calls (high risk of residual disease 
vs. lower risk of residual disease) compared with actual surgical outcomes (residual 
disease vs. R0) in the validation cohort. We used a 1-sided Fisher exact test to test 
the null hypothesis of equivalent rates of residual disease in the 2 groups against the 
alternative of increased incidence of residual disease in the predicted high-risk group. 
 
Quantitative RT-PCR analysis.  
Total RNA was extracted from the tumor tissues using the TRIzol® extraction 
method. RNA was then quantified using a nanodrop method and the 260/280 ratios 
were also checked to determine quality. RNA (1µg/sample) was reverse transcribed 
into cDNA using the Verso cDNA kit (Thermo Scientific, West Palm Beach, FL) 
according to the manufacturer's protocol. 
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qRT-PCR was performed on a 7500 PCR system (Applied Biosystems, Warrington, 
UK) using 1µL of cDNA for each sample. SYBR green (Applied Biosystems) was used 
to detect the products and 20pmoles of primer were used for the reaction. All reactions 
were carried out with 20µL of reaction mix and were performed in triplicate. We used 
the following primers: For FABP4, 5'-TGATGATCATGTTAGGTTTGGC-3' (forward) 
and 5'-TGGAAACTTGTCTCCAGTGAA-3' (reverse). For ADH1B, 5'- 
AGGGTAGAGGAGGCTGAAGA-3' (forward), 5'-ACCTGCTTCACTCTGGGAAA-3' 
(reverse). The PCR reactions were run under the following conditions: 50°C for 2 
minutes, 95°C for 15 minutes, followed by 40 cycles at 95°C for 1 minute each. All 
reactions were analyzed with the 7500 Applied Biosystems PCR software (v.2.0.5). 
The cycle threshold (Ct) values of the target genes were initially normalized to the Ct 
values of 18S rRNA and melt curves were checked to determine the specificity of the 
reactions. 
 
Cell line maintenance and siRNA and miRNA transfection 
All cancer cell lines were maintained at 37°C and 5% CO2 in culture with RPMI-
1640 or Dulbecco’s modified Eagle medium supplemented with 15% fetal bovine 
serum and 0.1% gentamicin sulfate (Gemini Bio-Products, Calabasas, CA, USA). The 
cell lines were obtained from American Type Culture Collection and were routinely 
tested for absence of Mycoplasma and were validated using Short Tandem Repeat 
DNA fingerprinting. All the in vitro experiments were performed at 60-80% cell 
confluence.  
27 
 
All siRNA transfections were conducted using Lipofectamine as a transfecting 
agent. SiRNA concentration of 100 nM was used, and the ratio of Lipofectamine (Life 
Technologies, Carlsbad, CA, USA) to a specific siRNA was 3:1. The cells were treated 
with siRNAs for 4 hrs in serum-free media before incubation in complete media for the 
specified time frame. For miRNA transfections (mimic and anti-miRNA), RNAiMAX 
(Life Technologies, Carlsbad, CA, USA was used as a transfection agent, and the 
ratio of RNAiMAX to a specific miRNA was 2:1. The concentration of miRNA-mimic or 
anti-miR was 40 nM concentration and the transfections were conducted in serum-
free conditions. After 4 hrs, the cells were incubated in complete media for the 
specified time frame. The sequences for siRNAs and miRNAs are listed in Table 2. 
 
In vivo models 
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY) 
and housed in pathogen-free conditions. The mice were cared for according to the 
guidelines of the American Association for Accreditation for Laboratory Animal Care 
International and the US Public Health Service Policy on Humane Care and Use of 
Laboratory Animals. All in vivo experiments and protocols were approved by MD 
Anderson’s Institutional Animal Care and Use Committee.  
For all in vivo experiments, cells were trypsinized at 60-80% confluence, 
neutralized with FBS-containing media and centrifuged at 1200 rotations per minute 
at 4°C for 6 minutes. The cells were then washed with phosphate-buffered saline 
(PBS) and reconstituted in Hank’s balanced salt solution (HBSS, Gibco, Carlsbad, 
CA, USA) to the desired concentration (1 × 106 cells/mouse in 50 µl for A2780 cells, 
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8 × 105 cells/mouse in 50 µl for luciferase-labelled HeyA8 MDR cells, 1 × 106 
cells/mouse in 50 µl for luciferase-labelled Ovcar 5 cells). Mice were anesthetized with 
ketamine, and an incision was made above the left ovary. The cells were directly 
injected into the ovary using a 1-ml tuberculin syringe with a 30-gauge needle. The 
incision was then closed using surgical clips and sutured to ensure complete closure 
of the surgery site. The mice were returned to cages until full recovery. Mice were 
given sustained-release buprenorphine subcutaneously for pain management, and 
the clips were removed after a week when the incision was completely healed. 
No therapeutic intervention was conducted in the experiment in which FABP4-
overexpressing cells were injected. For all therapeutic experiments, a siRNA or 
miRNA dose of 200 μg/kg was used, and the treatments were started 1 week after cell 
injections. The mice were divided into two groups: control and treatment, 10 
mice/group. Mice in the control group received control siRNA or control miRNA 
incorporated into neutral DOPC liposomes. Mice in the treatment group received 
FABP4 siRNA or a miR-409-3p mimic incorporated into DOPC liposomes. The doses 
were given twice weekly intraperitoneally. The mice were monitored daily for any toxic 
effects. Luciferase imaging was conducted to observe the effect of treatments on the 
metastasis as described previously [79]. Briefly, Imaging and data acquisition were 
performed with the IVIS Spectrum in vivo imaging system coupled to Living Image 
Software (Xenogen). The mice were first anesthetized in an acrylic chamber with a 
mixture of 1% isoflurane. They were then injected intraperitoneally with luciferin 
potassium salt (15 mg/ml) in PBS at a dose of 150 mg/kg body weight. A digital 
grayscale image was initially acquired, which was then overlaid with a pseudocolor 
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image representing the spatial distribution of detected photons emerging from active 
luciferase present within the animal. Signal intensity was expressed as a sum of all 
photons detected per second. Once a mouse in any group became moribund, all mice 
were euthanized. Mouse weight, tumor weight, number of nodules and locations of 
metastasis were recorded. Tumor tissues were then frozen in optimal cutting 
temperature media, fixed in formalin for paraffin embedding or snap-frozen.  
 
Liposomal nanoparticle preparation  
Incorporation of siRNA or miRNA into DOPC liposomes was achieved as 
previously described [80]. Briefly, DOPC and siRNA or miRNA were mixed at a ratio 
of 1:10 (w/w) in the presence of tertiary butanol. Tween 20 was added to the mixture 
at a ratio of 1:19. The mixture was vortexed and frozen in an acetone/dry ice bath and 
lyophilized. The lyophilized preparations were hydrated with PBS at room temperature 
to a concentration of 200 µg of siRNA or miRNA/kg per injection per mouse.   
 
MiRNA-mRNA expression association in TCGA OV samples 
TCGA cases were included if the patients had high-grade disease and no 
history of pre-treatment. TCGA gene expression quantification were produced using 
justRMA applied to the CEL files from TCGA (Affymetrix HT HG-U133A arrays, n = 
598) ([4]). TCGA miRNA microarray level 3 data (Agilent 8 x 15K Human miRNA-
specific microarray) was obtained from the Data Access Matrix. Data was available 
for 799 miRNAs. There were 541 samples meetings the inclusion criteria who had 
both gene expression and miR data available. The association between each probe 
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for the gene of interest and each available miRNA was assessed using the Maximal 
Information Coefficient (MIC) computed using MINE software of Reshef et al. [81]. 
 
MiRNA-mRNA Interactions  
We retrieved miRNA-target interaction information from miRWalk2.0 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/) that hosts miRNA-target 
predictions from twelve programs. We selected the cases predicted by at least seven 
algorithms (half of the total number of programs checked+1). The interaction between 
miR-409-3p and FABP4 (NM_001442) (3’ UTR) was predicted by nine programs 
(miRWalk, Microt4, miRanda, miRMap, miRNAMap, PITA, RNA22, RNAhybrid, 
Targetscan).  We used Perl to sort the information available and Latex to present the 
sites most probably to interact.   
 
Luciferase reporter assays, and FABP4 3′UTR site mutagenesis 
Luciferase assays were conducted as described previously [82]. Briefly, a 
GoClone pLightSwitch luciferase reporter for the 3’UTR of FABP4 was purchased 
from Switchgear Genomics (Menlo Park, CA, USA).  
HeyA8 MDR cells were transfected with control miRNA or miR-409-3p mimic 
(100 nM; Life Technologies, Carlsbad, CA, USA) with the help of FuGENE HD 
transfection agent. The cells were also transfected with 3’UTR reporter constructs and 
Cypridina TK controls (pTK-Cluc). After 24 h, the LightSwitch Dual Luciferase assay 
kit was used and the luciferase signal was measured using a microplate luminometer, 
as per the manufacturer’s guidelines (Biotek, Winooski, VT, USA). Luciferase activity 
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was normalized using the Cypridina TK control, and an empty 3’UTR construct was 
used as a negative control. The ratios were then normalized to the scrambled control 
miRNA. Mutant FABP4 3’UTR was created for the predicted binding site mentioned in 
Figure 21 using a QuickChange lightning multi-site-directed mutagenesis kit (Agilent 
Technologies, Santa Clara, CA, USA) using the primers mentioned in Table 2. The 
mutation was then confirmed using Sanger DNA sequencing before the mutant 
FABP4 3’UTR was used for the luciferase assay.  
 
Immunoblotting 
Protein lysates from tumor tissues or cultured cells were prepared using 
modified RIPA buffer containing proteinase and phosphatase inhibitors. Protein 
concentrations were determined using the BCA protein assay reagent kit (Pierce 
Biotechnology, Rockford, IL, USA). Lysates were loaded and separated on SDS-
polyacrylamide gels. The proteins were then transferred to a nitrocellulose membrane 
using a semidry electrophoresis procedure (BioRad Laboratories, Hercules, CA, 
USA). The membrane was blocked at room temperature for 1 h in 5% milk powder in 
Tris-buffered saline with Tween 20 (TBST) and then incubated at 4°C overnight with 
primary antibodies; FABP4 (catalog number HPA002188; Sigma) and vinculin as a 
loading control (catalog number V9131; Sigma). After washing with TBST, the 
membranes were incubated with horseradish peroxidase-conjugated horse anti-rabbit 
IgG (for FABP4) or anti-mouse IgG (for vinculin) (catalog numbers NA834 and NA931; 
1:2000; GE Healthcare) at room temperature for 2 h. An enhanced 
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chemiluminescence detection kit (catalog number NEL104001EA; Pierce 
Biotechnology) was used to visualize the horseradish peroxidase signal.  
 
Migration and invasion assay 
Modified Boyden chambers (Coster, MA, USA) were coated with 0.1% gelatin 
(migration) or defined basement membrane matrix (invasion). Defined basement 
membrane matrix (for invasion) was prepared in a 10-ml stock solution with laminin 
(50 µg/ml), 1 ml of type IV collagen (50 µg/ml), 0.2 ml of gelatin (2 mg/ml), and 4 ml 
and 4.8 ml of PBS. In the upper chamber, HeyA8 MDR and Ovcar 5 cells (0.7 × 105) 
suspended in 200 μl of serum-free media were added 48 h after siRNA/miRNA 
transfections or Tamoxifen treatments. In the upper chamber, complete media for cells 
containing 10% fetal bovine serum (500 μl) was added as a chemo-attractant. The 
chambers were incubated at 37°C in 5% CO2 for 6 h (migration assay) or 24 h 
(invasion assay). After incubation, the cells in the upper chamber were removed with 
cotton swabs. Cells were fixed, stained, and counted using light microscopy. Cells 
from five random fields were counted. Experiments were done in triplicate. 
 
Tumor samples 
High-grade ovarian tumor samples which are chemotherapy naïve were 
obtained after the study was approved by the Institutional Review Board, and written 
consent was obtained for the use of patient samples for research. 
 
miR-409-3p expression in patient tumor samples as taken from GEO dataset 
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The detailed method can be found in [83]. Briefly, 4 samples of HOSE (Normal 
primary ovarian surface epithelial cells taken from normal postmenopausal women) 
and 19 serous epithelial ovarian cancer samples were analyzed. The tumor samples 
were of high-grade and contained more than 70% malignant epithelial cellularity. The 
cloning frequency of a specific miR expressed as a fraction of total reads from a given 
samples was used to compare the relative expression of miRNAs between samples.  
 
In situ hybridization 
In situ hybridization was done as previously described in [82] . High grade 
serous ovarian cancer tissues which are chemotherapy naïve were selected. Xylene 
and an ethanol dilution series were used for deparaffinization and rehydration of the 
formalin-fixed, paraffin-embedded tissue sections. Tissue sections were digested with 
15 µg/ml proteinase K for 20 minutes at room temperature and then loaded onto 
Ventana Discovery Ultra (Tucson, AZ) for in situ hybridization analysis. The tissue 
slides were then incubated with a double-digoxigenin-labeled miRCURY LNA miRNA 
probe (Exiqon, Woburn, MA, USA) for 2 h at 55°C. Three percent H2O2 was used to 
inactivate endogenous peroxidases. After incubation with polyclonal anti-digoxigenin 
antibody and horseradish peroxidase-conjugated secondary antibody (Ventana), a 
tyramine-conjugated fluorochrome (TSA) reaction was performed for 12 minutes. 
Sequential TSA rounds were performed for the detection of proteins using the same 
protocol. Slides were mounted with antifading ProLong Gold Solution (Life 
Technologies). 
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Immunostaining 
Paraffin-embedded sections (5 µm) of tumor tissues were cut and used for 
detection of FABP4. Formalin-fixed sections were deparaffinized by sequential 
washings with xylene, 100% ethanol, 95% ethanol, 80% ethanol, and PBS. A suitable 
antigen retrieval method was used. Endogenous peroxidase was blocked by 
incubating the slides with 3% hydrogen peroxide in PBS. Nonspecific binding was 
prevented by incubating the slides with 4% fish gelatin. This was followed by 
incubation with primary antibody overnight at 4°C. The next day, the slides were 
washed with PBS and incubated with suitable secondary antibody (goat anti-rabbit 
horseradish peroxidase antibody diluted in protein block solution) for 1 h at room 
temperature. The slides were then washed with PBS followed by development with 
3,3'-diaminobenzidine. The nuclei were stained with Gill’s hematoxylin solution and 
the slides were then mounted.  
 
Quantitative real-time PCR 
Total RNA was extracted from the tumor tissues using the Direct-Zol RNA 
extraction kit (Zymo Research, Irvine, CA, USA). RNA was then quantified using a 
NanoDrop spectrophotometer method and the 260 nm/280 nm ratios were checked 
to determine quality. RNA (1 µg per sample) was reverse-transcribed into cDNA using 
the Verso cDNA kit (Thermo Scientific, West Palm Beach, FL, USA) according to the 
manufacturer’s protocol. 
Quantitative real-time PCR was performed on a 7500 PCR system (Applied 
Biosystems, Warrington, UK) using 1 µl of cDNA for each sample. SYBR green 
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(Applied Biosystems) was used to detect the products, and 20 pmol of primer was 
used for the reaction. All reactions were carried out with 20 µl of reaction mix and 
performed in triplicate. We used the primers mentioned in Table 2. The following 
conditions were used for PCR: 50°C for 2 minutes, then 95°C for 15 minutes, followed 
by 40 cycles at 95°C for 1 minute each. All reactions were analyzed using the 7500 
Applied Biosystems PCR software (v.2.0.5). The cycle threshold values of the target 
genes were initially normalized to the cycle threshold values of 18S rRNA, and melt 
curves were checked to determine the specificity of the reactions. 
For miRNA quantifications, Taqman miRNA assays (Life Technologies) were 
used and reverse-transcription real-time PCR was performed, according to the 
manufacturer’s instructions. RNU6B was used as a housekeeping gene. 
 
Copy number analysis 
TCGA mRNA microarray (Agilent 244K Custom Gene Expression G4502A-07,  
Affymetrix Human Genome U133A 2.0 Array, Affymetrix Human Exon 1.0 ST Array) 
and RNASeqv2 level 3 and clinical data were retrieved from Broad GDAC Firehose 
http://gdac.broadinstitute.org/. Putative copy-numbers from GISTIC were retrieved 
from cbio portal (http://www.cbioportal.org/).   To find the relationship between FABP4 
expression and copy number, we first employed a Shapiro-Wilk test and verified that 
the data doesn’t follow a normal distribution. The nonparametric test Kruskal-Wallis 
test, was applied and no relationship between FABP4 and copy-number could be 
established. A box-and-whisker plot (Box plot represents first (lower bound) and third 
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(upper bound) quartiles, whiskers represent 1.5 times the interquartile range) was 
used to visualize the data (log2(x)).   
 
Correlation of FABP4 with genes from hypoxia metagene signature 
The Spearman's rank-order correlation test was applied to measure the 
strength of the association between FABP4 and the genes from the Winter et al. 
hypoxia metagene[84]. We imposed a cut-off of functional relevance on the Spearman 
correlation coefficient in absolute value of 0.2 based on the method published 
previously [85]. 
 
Correlation of FABP4 expression with metabolites present in patient tumor 
samples.  
The metabolomics data and the gene expression data (normalized log values) 
were taken from [58, 86, 87]. High grade serous ovarian cancer tumor samples (n=66) 
were analyzed. The samples were divided into high or low FABP4 group based on the 
median expression of FABP4 in all the samples. Similarly a median value for each 
metabolite was calculated for high or low FABP4 samples. The comparison is 
presented as antilog values.  
 
DESI-MS imaging 
DESI-MS imaging was conducted as described previously [88]. A 2D Omni 
Spray (Prosolia Inc., Indianapolis, IN) coupled to an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Scientific, San Jose, CA) was used for tissue imaging. DESI-
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MS imaging was performed in the negative and positive ion mode from m/z 100 to 
1500, using a hybrid LTQ-Orbitrap mass spectrometer which allows for tandem MS 
experiments, high mass accuracy (<5 ppm mass error), and high mass resolution 
(240,000 resolving power) measurements. The spatial resolution of the imaging 
experiments was 200 µm. Spatially accurate ion images were assembled using 
BioMap and MSiReader software. The histologically compatible solvent system 
dimethylformamide:acetonitrile (DMF:ACN) 1:1 (v/v) was used for negative ion mode 
analysis, at a flow rate of 1.2 µl/min. For positive ion mode analysis, pure ACN was 
used, at a flow rate of 3 µl/min. The N2 pressure was set to 185 psi. For ion 
identification, high mass resolution/accuracy measurements using the same tissue 
sections analyzed were conducted. Tandem MS analyses were performed using both 
the Orbitrap and the linear ion trap for mass analysis.  
 
Histopathology and light microscopy 
The same tissue sections analyzed by DESI-MS imaging were subjected 
afterwards to standard H&E staining protocol. Light microscopy images of the H&E 
stained slides were taking using the EVOS FL Auto Cell Imaging System (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA). 
 
Effect of Tamoxifen on expression of FABP4 
The drug was dissolved in DMSO and physiologically achievable 
concentrations were used for the experiments. HeyA8 MDR cells were plated in 24 
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well plates and serum starved before tamoxifen treatment. The cells were collected 
and RNA was extracted for qRT-PCR. 
 
Free fatty acid uptake assay 
The experiment was conducted as per the manufacturer’s instructions (Free 
Fatty Acid Uptake Assay Kit (Fluorometric, ab176768) Cambridge, MA, USA). The 
cells were serum starved and treated with tamoxifen at a desired concentration. Then 
the fatty acid dye loading solution was added (100µl/ well of a 96 well plate). The 
florescence signal was measured at Ex/Em 485/515 nm using a bottom read mode 
after 30 minutes incubation at room temperature. 
 
Survival analysis 
Survival analysis was performed in R (version 3.2.5) using Tothill data set. The 
relationship between overall survival, respectively progression free survival and 
covariates (mRNA expression levels and clinical parameters (age and stage) was 
examined using a Cox proportional hazard model. A multivariate Cox proportional 
hazard model was fitted, including the clinical parameters and mRNA expression 
significant in the univariate analysis.     
 
Statistical Analysis 
MS data corresponding to the areas of interest were extracted using 
MSiReader software. The m/z range was discretized by performing hierarchical 
clustering and cutting the resulting dendrogram at distance 0.05. Peaks appearing in 
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more than 10% of the pixels were kept for analysis.  Logistic regression was performed 
with Lasso regularization using the “glmnet” package (26) in the R language. 
Regularization parameters were determined by 3-fold cross-validation analysis. The 
data were randomly equally divided into training and validation sets of samples, 50-
50 per patient basis. For other assays, Student’s t-test was performed to examine 
the difference between the control and treatment groups. A P value less than 0.05 
was deemed statistically significant. All the statistical tests were two-sided. Error 
bars represent standard error from triplicates. 
siRNA Sequence 
Control siRNA 5'-UUAUGCCGAUCGCGUCACATT-3'  
3'-TTAAUACGGCUAGCGCAGUGU-5' 
FABP4 siRNA seq 1 5’-GACGUUGACCUGGACUGAAdTdT-3’ 
3’-UUCAGUCCAGGUCAACGUCdTdT-5’ 
FABP4 siRNA seq 2 5’-GUGGGAUAUAUUGUUCAAAdTdT-3’ 
3’-UUUGAACAAUAUAUCCCACdTdT-5’ 
 
Primers Primer sequences 
18S 5’CGCCGCTAGAGGTGAAATTC3’ (forward) and 
5’TTGGCAAATGCTTTCGCTC3’ (reverse) 
FABP4 5'-TGATGATCATGTTAGGTTTGGC-3' (forward) and 5'-
TGGAAACTTGTCTCCAGTGAA-3' (reverse) 
Mutated  CAACAATATCTTTTTGAACAATATATCCCACAGGCGACGGTAGAGTTCAAT
GCGAACTTCAGTCCAGGTCAA (forward) 
TTGACCTGGACTGAAGTTCGCATTGAACTCTACCGTCGCCTGTGGGATAT
ATTGTTCAAAAAGATATTGTTG (reverse) 
 
Table 2 siRNA and primer sequences used in the study   
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Chapter 3: Molecular biomarkers for prediction of residual disease in ovarian 
cancer 
We used two publicly available datasets –TCGA and Tothill [77, 78] containing 
samples of HGSOC (High grade serous ovaria cancer). We set up specific inclusion 
and exclusion criteria for our analysis. We excluded samples if they were from 
recurrent tumors, metastatic sites or normal tissues. We also excluded the tumors that 
were not of high grade serous histology or were taken from patients who had 
undergone neoadjuvant chemotherapy. From the two datasets, we thus selected 491 
(TCGA) and 189 (Tothill) cases that met our criteria (Tumors that were taken from 
primary site i.e. ovary, are chemotherapy naïve and are of stage 3 and above from 
high grade serous histological subtypes). 
From the TCGA dataset, 77% of the patients had RD while 74% of the patients 
from the Tothill dataset had residual disease. We then analyzed the patient survival 
data for these cases. We initially grouped them into 4 groups based on the size of the 
residual disease   >20mm (n=102), 11-20mm (n=34), 1-10mm (n=242), No 
macroscopic disease (n=113) for TCGA and macro-size NK/ exact size unknown 
(n=13), >1cm (n=57), <1cm (n=66), nil (n=50) for Tothill dataset. Figure 7 (a and b) 
shows the survival differences among these different groups. When we compared 
overall survival of patients with R0 versus any RD (other 3 groups combined), we 
noticed that R0 patients had significantly better overall survival compared to the rest 
(Figure 7 c and d), p<0.0001 and p<001 for TCGA and Tothill respectively. 
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Figure 7 Overall survival for the patients with high grade serous ovarian cancer, 
grouped according to the size of the residual disease after primary debulking surgery. 
TCGA (a) and Tothill (b) datasets were investigated. Analysis of TCGA (c) and Tothill 
(d) patient datasets from the comparison of R0 to any residual disease (RD). 
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We then used the clinical information of RD status and gene expression data 
for the tumor samples collected from TCGA and Tothill datasets to identify genes 
associated with increased incidence of residual disease. We only used the probe sets 
that are common in TCGA and Tothill sets and recorded the mean expression of the 
gene in RD group and R0 group. Table 3 shows the list of 47 probe sets (associated 
with 38 genes) that have differences in their expression between RD and R0 group at 
10% false discovery rate. 
Gene Probe set 
ADAM12 213790_at 
ADH1B 209612_s_at 
ADH1B 209613_s_at 
ADIPOQ 207175_at 
ALDH1A3 203180_at 
ALDH5A1 203609_s_at 
AQP1 209047_at 
BCHE 205433_at 
COL11A1 37892_at 
COL16A1 204345_at 
COL3A1 201852_x_at 
COL5A1 203325_s_at 
COL6A2 213290_at 
COL8A1 214587_at 
CRISPLD2 221541_at 
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CXCL12 203666_at 
CXCL12 209687_at 
CYR61 201289_at 
DCN 201893_x_at 
DCN 209335_at 
DCN 211813_x_at 
DCN 211896_s_at 
ETV1 221911_at 
FABP4 203980_at 
FAP 209955_s_at 
GADD45B 207574_s_at 
GADD45B 209304_x_at 
GADD45B 209305_s_at 
GFPT2 205100_at 
GREM1 218468_s_at 
GREM1 218469_at 
KCNE4 222379_at 
LUM 201744_s_at 
NBL1 201621_at 
NBL1 37005_at 
NFYA 204107_at 
OMD 205907_s_at 
PDGFD 219304_s_at 
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PDLIM3 209621_s_at 
PDPN 221898_at 
POLR1C 207515_s_at 
PTGIS 208131_s_at 
SVEP1 213247_at 
TIMP3 201150_s_at 
VGLL3 220327_at 
VSIG4 204787_at 
XYLT1 213725_x_at 
 
Table 3 List of 47 probe sets that have different expression in R0 and RD groups and 
are common between TCGA and Tothill datasets (10% false discovery rate) 
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When the false discovery rate was lowered to 5%, we identified 8 genes that 
differed in their expression between RD vs. R0 groups and were common in TCGA 
and Tothill dataset. Figure 8 shows the heatmaps of the expression of those 8 genes 
for TCGA (a) and Tothill (b) sets. 
 
Figure 8 Heatmaps showing expression of top 8 genes that have different expression 
between R0 and RD groups as observed in TCGA (a) and Tothill (b) datasets. (<5% 
false discovery rate). The color bars at top indicate residual (red) or non-residual (blue) 
cases. The red and blue bars within the map indicate high and low gene expression 
respectively. High expression of FABP4 and ADH1B correlate with residual disease 
incidences while low expression correlate with R0 incidences. The expression of 
FABP4 and ADH1B correlate well with each other. 
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We then investigated the density plots of the 8 genes presented in Figure 7. 
We noticed that for FABP4 and ADH1B, the expression distribution was bimodal, as 
opposed to the distribution of other genes which did not show a qualitative shift in their 
expressions in RD and NoRD cases. For FABP4 and ADH1B, many samples had low 
expression of these genes, however for a small set of samples, the expression was 
very high. Nearly all the samples above a certain level of expression have RD. Figure 
9 shows gene expression and RD status for FABP4, ADH1B in TCGA and Tothill sets.  
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Figure 9 Dot and density plots for FABP4 (TCGA (a) and Tothill (b)) and ADH1B 
(TCGA (c) and Tothill (d)) Cases with residual disease are represented in red while 
non-residual disease is indicated in blue. Y axis represents normalized expression of 
FABP4 or ADH1B and X axis represents number of samples from TCGA or Tothill 
datasets. Increased rates of RD (red dots) is observed at high expression of FABP4 
and ADH1B.  
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We then decided to explore the joint distribution of gene expression of FABP4 
and ADH1B (Figure 9). We measured the RD status when the expression of both-
ADH1B and FABP4 was high (using 3.5 as a cut of for both the genes). In TCGA 
samples, 97 out of 107 (90.6%) samples belonging to the ‘high expression’ group had 
RD whereas 281 out of 384 (73.2%) samples having low gene expression of ADH1B 
and FABP4 had RD. Among the Tothill samples, 59 out of 63 samples (93.7%) of high 
expression group had RD while 80 of 126 samples (63.5%) of low expression had RD.  
 
Figure 10 Plots of FABP4 and ADH1B for TCGA (a) and Tothill (b) datasets. The rates 
of residual disease (red dots) are higher when both the genes are elevated  
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After identification of 2 possible biomarkers from the computational analysis, 
we decided to perform validation studies in an independent cohort using qRT-PCR 
method to determine gene expression. We examined 139 patient tumor samples from 
two institutes- MD Anderson Cancer Center and Fred Hutchinson Cancer Research 
Center. All the samples were chemotherapy naïve. We initially checked the expression 
of ADH1B and FABP4 in omental samples as well and compared the gene expression 
between ovarian and omental samples. Figure 11 shows the density plots for ADH1B 
and FABP4 for both the tissues. For both the genes, the expression was higher in 
omental tissues compared to ovarian tissues. 
 
Figure 11 Density plots of FABP4 (a) and ADH1B (b) in ovary (red) and omental (gray) 
as observed in qRT-PCR experiments  
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We also checked FABP4 expression for 4 cases for which paired ovarian and 
omental samples were available. In all these samples, omental gene expression was 
higher than ovarian gene expression. (Percent difference- 2%, 85%, 110%, 131%). 
We therefore decided to only focus on the samples from primary site a) To be 
consistent with TCGA and Tothill data set b) The gene expressions were not 
comparable between these two sites and cannot be analyzed using a same cut-off 
values. The analyses of gene expression and RD were double-blinded. The qRT-PCR 
values for ADH1B and FABP4 gene expression and RD statuses are presented in 
Figure 11. As observed in the TCGA and Tothill datasets, the expression levels of 
ADH1B and FABP4 were highly correlated with each other. However, the distribution 
of these genes was different from the one observed in the microarray data of TCGA 
and Tothill sets. The data from qRT-PCR analysis was not bimodal as observed in the 
previous microarrays. Therefore, we decided to specify a threshold to determine which 
samples will be grouped in high or low expression groups. Based on the power 
calculations, we decided that 25% of the samples with the highest FABP4 expression 
will be grouped together and we predicted that this group will have higher probability 
of having RD compared to the rest of the samples. After unblinding the data and 
correlating gene expression with RD statuses, we noticed that 30 out of 35 patients 
predicted to have RD, had residual disease (PPV 86%). On the other hand, 54 out of 
104 from the low FABP4 group had residual disease (PPV 52%). The odds ratio was 
5.5 and the difference was significant (p=0.0002) using one sided Fischer’s exact test 
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(Figure 12b). 
 
Figure 12 (a) Plot of qRT-PCR values for FABP4 and ADH1B for the ovarian validation 
samples. The solid line is the cutoff used for blinded validation while the dashed line 
is the cutoff determined after weighting two genes equally (b) Prediction results for the 
validation cohort after dividing the samples in high and low FABP4 groups 
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When we further explored the relationship between ADH1B or FABP4 gene 
expression and residual disease status (Figure 13 a and b), we noticed a continuous 
trend of increasing incidence of RD observed with increase in gene expression. For 
example, RD rate across the 4 groups of FABP4 genes was 41% (14/34, lowest 
quartiles), 63% (22/35), 51% (18/35) and 86% (30/35, top most quartile)  
 
Figure 13 Plots showing incidence of RD as a function of expression of FABP4 (a) 
and ADH1B (b), based on qRT-PCR values from the validation cohorts. The points 
show the incidence of RD for each group plotted at the mean value of FABP4 or 
ADH1B per group. Horizontal and vertical lines indicate standard deviations 
Our molecular biomarkers thus accurately predicted RD incidences in high 
grade serous ovarian cancer.  
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Chapter 4: Effects of FABP4 on tumor progression  
After establishing the importance of FABP4 as a molecular biomarker, we next 
explored if it has any functional role in tumor progression. We first silenced FABP4 in 
HeyA8 MDR cells using FABP4 siRNA and made sure that we have achieved 
significant FABP4 inhibition. We then conducted migration and invasion assays to 
examine the effect of FABP4 knockdown on key steps in tumor metastasis.  
After FABP4 siRNA transfection, there was 85-90% knockdown of FABP4. As 
seen in Figure 14 (a and b) there was a significant reduction in the ability of cells to 
migrate (p<0.01) or invade (p<0.01) after FABP4 knockdown. We also conducted 
proliferation assay to make sure that the effect on migration and invasion is not a result 
of stunted cell proliferation. There was no significant difference in cell proliferation after 
FABP4. We then investigated the effect of ectopic expression of FABP4 in cancer 
cells. In A2780 cells, ectopic FABP4 expression led to increase in migration (p<0.05) 
and in invasion (p<0.01) (Figure 14 c and d). 
The effect was also observed in additional cell lines such as Ovcar 5 and when 
we used additional siRNA sequence. In Ovcar 5 cells, knockdown of FABP4 resulted 
in significant reduction in migration (p<0.05) and inhibition (p<0.05) of the cells treated 
with siFABP4 (Figure 14 e and f). The second sequence of siRNA was able to ~60% 
decrease in migration (P<0.01) and ~65%decrease in invasion (p<0.01) (Figure 14 g 
and h). Figure 14 i, j, k show the validation of FABP4 knockdown in the cells.  
. 
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Figure 14 (a, b) Effect of knockdown of FABP4 on the (a) migration and (b) invasion 
of ovarian cancer cells (HeyA8 MDR). **p < 0.01. (c, d) Effect of increased expression 
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of FABP4 on the (c) migration and (d) invasion of cancer cells (A2780-ip1). *p<0.05. 
**p < 0.01. (e, f) Effect of FABP4 knockdown on (e) migration and (f) invasiveness 
using a second siRNA sequence. **p<0.01. (g, h) Effect of FABP4 knockdown on (g) 
migration and (h) invasion in Ovcar 5 cells. *p < 0.05. Validation of FABP4 knockdown 
is shown for HMDR cell line FABP4 sirna (i) seq 1 (j) seq 2 (k) Ovcar 5 cell line  
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Since the in vitro studies were promising, we decided to see if FABP4 promotes 
tumor progression in in vivo settings. We first established a cell line (A2780) 
ectopically expressing FABP4. We then injected control cells and cells ectopically 
expressing FABP4 in the ovaries of nude mice and examined the effect of FABP4 on 
promoting tumor burden and metastasis. Compared to subcutaneous or intra-
peritoneal injections, this orthotopic model closely mimics the cancer progression as 
seen in ovarian cancer patients [89, 90]. There was no therapeutic intervention for this 
study and the mice were sacrificed when any mouse became moribund. There was a 
significant difference in tumor weight and number of nodules between control and 
ectopic FABP4 group (Figure 15 a and b).We then analyzed H&E sections of the 
tumors collected from these mice. We noticed that while tumors in the control group 
did not invade the normal tissues, tumors from ectopic FABP4 group were highly 
infiltrative (Figure 15 d). The metastatic pattern was also unique in the ectopic FABP4 
group (Figure 15 e). In the control group, the tumor was mainly located in ovary, 
peritoneum and mesentery whereas the metastasis in ectopic FABP4 was also 
observed in diaphragm, liver, pelvis. As expected, immunohistochemical analysis 
showed that FABP4 was indeed overexpressed in the tumors from ectopic FABP4 
group (Figure 15 f). 
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Figure 15 (a) Aggregate mass of tumors in orthotopic mouse models involving A2780-
ip1 cells transfected with control and FABP4 ectopic expression vectors (n = 10 mice 
per group, Student t test). **p < 0.01. (b) Effect of ectopically expressed FABP4 on 
the number of nodules in orthotopic mouse models involving A2780-control and 
A2780-FABP4 ectopic expression (n = 10 mice per group, Student t test). **p < 0.01. 
(c) Representative images of nodules are shown on the right. (d) Representative 
hematoxylin and eosin-stained sections of tumor tissues from mice injected with 
control A2780-ip1 cells or A2780-ip1 cells transfected with FABP4-expressing vector. 
(e) Distribution of metastatic nodules present in the groups (f) Immunohistochemical 
expression of FABP4 in tumor tissues from mice injected with control A2780-ip1 cells 
or A2780-ip1 cells with ectopic expression of FABP4.  
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The next step was to investigate the effects of FABP4 knockdown on tumor 
progression. We used luciferase labeled HeyA8 MDR cell lines and performed intra-
ovarian cell injections to establish orthotopic mouse model of ovarian cancer. A week 
after the cell injections, we randomly divided the mice in two groups, one would receive 
control siRNA encapsulated in DOPC nanoliposomes while the other group would 
receive FABP4 siRNA encapsulated in DOPC nanoliposomes. The intra-peritoneal 
DOPC injections were given twice weekly and the mice were sacrificed when any 
mouse became moribund. At the end of the study, tumor weight, number of nodules, 
locations of metastasis and weight of the mice were measured. As shown in Figure 
16 a and b, FABP4 knockdown led to a significant reduction in tumor weight and 
number of nodules. The metastasis was widespread in the control mice but was only 
observed in the ovaries and peritoneal areas of mice injected with FABP4 siRNAs 
(Figure 16 e). Bioluminescence images also supported the results. There was a 
significant difference in luciferase readings between control mice and mice injected 
with FABP4 siRNA (Figure 16 f). We also examined the tumor tissues for FABP4 
expression. The treatment with FABP4 siRNA achieved significant knockdown of 
FABP4 in mice as shown with immunohistochemistry and western blot (Figure 16 g 
and h). We also recorded weight of the mice in these two groups and noticed that the 
treatment did not have any effect on the mice weight (Figure 16d). 
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Figure 16 (a) Aggregate mass of tumors in orthotopic mouse models involving HeyA8 
MDR cells. Mice were treated with control or FABP4 siRNA encapsulated in DOPC 
liposomes (n = 10 mice per group). **p < 0.01. (b) Effect of knockdown of FABP4 on 
the number of metastatic nodules in HeyA8 MDR orthotopic mouse models. ***p < 
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0.001. (c) Representative images are shown on the right. (d) Mouse weight in the 
control and treatment groups. (e) Distribution of metastatic nodules present in 
individual mice after treatment with control or FABP4 siRNA encapsulated in DOPC 
liposomes. (f) Representative images of metastatic lesions revealed by luciferase 
imaging, and quantitative assessment of luciferase signal from mice treated with 
control or FABP4 siRNA encapsulated in DOPC nanoliposomes. *p<0.05. (g) 
Immunohistochemical staining showing FABP4 protein expression levels at the 
primary site (ovary) and metastatic sites after treatment with control or FABP4 siRNA. 
(h) FABP4 protein expression levels at the primary site (ovary) and metastatic sites 
after treatment with control or FABP4 siRNA, as shown in Western blot analysis. OD-
Optical Density. 
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We also examined additional orthotopic mouse model. This time, we used 
Ovcar 5 cell line, the siRNA treatment was similar to the one described above. At the 
end of the study, we noticed significant inhibition of tumor progression in FABP4 
siRNA treatment group. There was a significant reduction in tumor weight (Figure 17 
a), number of nodules (Figure 17 b) and metastasis was also restricted to ovary and 
mesentery unlike the extensive metastasis seen in control mice (Figure 17 c). The 
treatment did not have any deleterious effect on body weight of mice (Figure 17 d). 
 
Figure 17 (a) Aggregate tumor weight for mice injected with Ovcar 5 cell line. The 
mice were treated with control siRNA or FABP4 siRNA encapsulated in DOPC 
nanoliposomes. *p<0.05. (b) Effect of knockdown of FABP4 on the average number 
of nodules. **p<0.01. (c) Pattern of metastasis in the control and treated mice. (d) 
Mouse weight in the control and treatment groups. 
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Aggressive cytoreduction as attempted in patients is not feasible in mice. To 
determine if FABP4 knockdown affects the likelihood of achieving no residual status, 
we calculated a score based on the metastasis pattern seen in the orthotopic mouse 
models. We based our scoring schema on the one developed by Fagotti et al. [36].  
The original schema assigns a score between 0-2 based on the extent of metastasis 
at a given location. Studies have shown that the scores correlate with the residual 
disease status in ovarian cancer patients [37, 38]. Figure 1 represents original 
schema. Like Fagotti score, our modified scoring system (Figure 18 a) assigns a score 
of 2 for each metastasis location and if the combined score for a specific mouse is 
greater than or equal to 8, it was considered a case of residual disease. Conversely, 
score below 8 indicated that R0 status. We calculated scores for each of the mouse 
from the two in vivo experiments described above. Ectopic expression of FABP4 led 
to higher scores in mice compared to the control mice (Figure 18 b). In the second in 
vivo experiment, most of the mice treated with control siRNA had scores of 8 indicating 
increased likelihood of residual disease; while all the mice treated with FABP4 siRNA 
had scores below 8 (Figure 18 c). All the in vitro and in vivo experiments thus 
established the key role FABP4 plays in residual disease occurrences in ovarian 
cancer. 
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Figure 18 (a) Scoring schema for the modified Fagotti score (b) Modified Fagotti 
scores for each mouse in the control and ectopicFABP4 groups. (c) Modified Fagotti 
scores for each mouse in the control siRNA and FABP4 siRNA groups. (Ov-Ovary, 
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Perit-Peritoneum, M-Mesentery, S-Spleen, PS-Para-splenic area, H-Liver, PH-Para-
hepatic area, D-Diaphragm, LN-Lymph node, PALN-Para-aortic lymph nodule, om-
Omentum)  
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Chapter 5: Upstream regulation of FABP4 
We next investigated the upstream regulation of FABP4 in ovarian cancer. We 
first analyzed TCGA data and checked if there is any correlation between copy 
number and mRNA expression of FABP4. We investigated the data across various 
platforms (Affymetrix Agilent, RNAseq2) however, there was no correlation between 
copy number and FABP4 expression in TCGA ovarian cancer samples (Figure 19).  
  
Figure 19 Correlation between copy number and mRNA expression levels of FABP4 
across platforms (Affymetrix, Agilent, RNAseqv2) using data from The Cancer 
Genome Atlas. 
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We then compared FABP4 expression in ovarian cancer cell lines and 
compared it with that of the tumor tissues taken from mice injected with the same cell 
line. We noticed that FABP4 expression in tumor tissues is significantly higher 
compared to its expression in the cell lines. We thus checked the effect of tumor micro-
environmental factors on the expression of FABP4. We checked if 3D arrangement of 
cells in the tumor tissue has any role in increasing FABP4 expression in vivo. The 
effect was significant when compared to the cells grown in 2D condition, however it 
was not consistent and did not validate in other cell lines. Effect of stromal cell lines 
and hypoxia (Figure 24a) is discussed later in the next chapter. We also tested the 
possibility of transcriptional regulation of FABP4. We analyzed TCGA dataset and 
selected transcriptional factors (ISX, MSX, FOXA1) that had the highest correlation 
with FABP4 expression across 3 platforms (Affymetrix, Agilent and Illumina). 
Knockdown of some transcription factors resulted in downregulation of FABP4 thus 
suggesting possible regulation by these factors but the chromatin immunoprecipitation 
assay did not show binding between the selected transcription factor and the promoter 
region of FABP4.  
We thus decided to explore the possibility of miRNA regulation. We 
systematically analyzed TCGA data to select the potential miRNAs regulating FABP4. 
The selection process is explained in Figure 20a. We selected chemotherapy naïve, 
high grade serous ovarian cancer samples from TCGA set. We then probed miRNA 
data and selected miRNAs that have some association with FABP4 mRNA. We used 
MIC (maximal information coefficient) scores to select miRNAs. In this system, a score 
of 0 represents there is no association between a given miRNA and the expression of 
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gene while a score 1 indicates a perfect association between a miRNA and a gene. 
The miRNAs with MIC > 0.2 were selected for further analysis. We used prediction 
softwares to investigate which of these selected miRNAs are predicted to target 3’UTR 
of FABP4. Table 4 lists the 32 miRNAs that had MIC scores of > 0.2 with FABP4 and 
also lists the number of prediction softwares that predicted their interaction with 
FABP4. After 2 selection criteria, we selected miR-409-3p which was predicted to 
target FABP4 by the highest number of softwares (9 prediction softwares). 
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Figure 20 (a) Flowchart showing the methods used to identify microRNAs (miRNAs) 
that target FABP4 in ovarian cancer. (b) Effect of miR-409-3p mimic transfection 
specifically on FABP4 expression levels (RNA) in HeyA8 MDR cells. (c) Effect of miR-
409-3p mimic transfection on FABP4 expression levels (protein) in HeyA8 MDR 
cells.(d) Effect of miR-409-3p mimic transfection on the expression of FABP4 in Ovcar 
5 cells. **p<0.01. (e) Effect of miR-409-3p mimic transfection on the expression of 
FABP4 in Ovca 432 cells. *p<0.05. (f) Effect of miR-409-3p inhibitor on the expression 
of FABP4 mRNA (left) and on the level of miR-409-3p (right) in Ovcar 3 cells. *p < 
0.05.   
 
MicroRNA MIC score Number of softwares 
predicting miR-409-3p and 
3’ UTR of FABP4 
hsa-miR-143 0.270601 2 
hsa-miR-126 0.22939 5 
hsa-miR-214* 0.22323 1 
hsa-let-7g* 0.22284 1 
hsa-miR-199a-5p 0.22044 1 
hsa-miR-409-3p 0.21971 9 
hsa-miR-507 0.21927 1 
hsa-miR-145* 0.21636 1 
hsa-miR-214 0.21551 1 
hsa-miR-1225-3p 0.21542 - 
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hsa-miR-431 0.21531 2 
hsa-miR-342-3p 0.21100 1 
hsa-miR-199b-5p 0.21077 1 
hsa-miR-145 0.21002 1 
hsa-miR-150 0.20990 4 
hsa-miR-133a 0.20808 1 
hsa-miR-409-5p 0.20784 0 
hsa-miR-199b-3p 0.20771 2 
hsa-miR-22 0.20767 1 
hsa-miR-22* 0.20705 1 
hsa-miR-133b 0.20703 1 
hsa-miR-1 0.20599 2 
hsa-miR-1225-5p 0.20435 1 
hsa-miR-514 0.20427 - 
hsa-miR-132 0.20395 1 
hsa-miR-152 0.20356 3 
hsa-miR-432 0.20268 1 
hsa-miR-508-3p 0.20240 2 
hsa-miR-139-5p 0.20203 1 
hsa-miR-379 0.20181 1 
hsa-miR-182 0.20142 1 
hsa-miR-143* 0.20019 1 
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Table 4. miRNAs with MIC scores greater than 0.2 for association with FABP4 gene 
expression 
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We then checked the effect of miR-409-3p on FABP4 expression in vitro. We 
transfected HeyA8 MDR cells with miR-409-3p mimic and observed 85% reduction in 
FABP4 mRNA levels (p<0.01) (Figure 20 b). We saw a similar effect at protein level 
(Figure 20 c). The effect was also observed in additional cell lines. In Ovcar 5 (Figure 
20 d) and Ovca 432 cells (Figure 20 e), FABP4 levels were reduced after miR-409-3p 
mimic transfection (p<0.01 and p<0.05 respectively).Conversely, when we transfected 
Ovcar 3 cells with anti-miR-409-3p, we observed an increase in the expression of 
FABP4 (Figure 20 f). There was 40% inhibition (Figure 20 g) after anti-miR-409-3p 
transfection which resulted in a significant increase in FABP4 expression (p<0.05). 
The next step was to investigate whether miR-409-3p binds to 3’UTR of 
FABP4. The binding site for miR-409-3p on 3’UTR of FABP4 is shown in Figure 21 a 
and the mutated sequence is shown in Figure 21 b. We conducted luciferase assays 
to answer this question. We transfected HeyA8 MDR cells with plasmids containing 
empty 3’UTR or 3’UTR of FABP4. The cells were then transfected with control miR or 
miR-409-3p. When the luciferase activity was measured, we observed that the activity 
was significantly lower for cells transfected with 3’UTR of FABP4 and miR-409-3p 
compared to the controls (Figure 21 c) thus indicating that miR-409-3p binds to 3’UTR 
of FABP4. We then mutated the sequence of 3’UTR of FABP4 where miR-409-3p is 
predicted to bind. As observed earlier, there was a significant reduction in the 
luciferase activity in the cells transfected with 3’UTR of FABP4 and miR-409-3p 
however there was no significant difference between the controls and the cells 
transfected with mutated 3’UTR of FABP4 suggesting that miR-409-3p can longer to 
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bind to the mutated binding site of 3’UTR of FABP4 (Figure 21 d) . Thus luciferase 
assay confirmed that miR-409-3p can bind to 3’UTR of FABP4.  
We next assessed the expression of miR-409-3p in ovarian cancer cell lines 
and compared it with its expression in normal ovarian cell line (HIO180). We noticed 
that the expression of miR-4093p is significantly lower in the cancer cell lines 
compared with the normal ovarian cell line (Figure 21 e). We also compared miR-409-
3p expression in ovarian tumor tissues and normal ovarian tissue using Gene 
Expression Omnibus dataset (GSE15190) [83] (Figure 21 f). This data set also 
revealed that tumor samples have low expression of miR-409-3p compared to the 
normal tissues. We then examined 8 ovarian cancer patient tumor samples from the 
Gynecology Oncology Dept. of M.D. Anderson Cancer Center. We used in situ 
hybridization technique to analyze the expression of FABP4 and miR-409-3p. We saw 
a distinct inverse association between miR-409-3p and FABP4 expression levels in 
the in situ hybridization images (Figure 21 g).  
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Figure 21 (a) Predicted binding site of miR-409-3p on the 3’ untranslated region (UTR) 
of FABP4. (b) Original and mutated 3’ untranslated region (UTR) sequence of FABP4, 
where miR-409-3p is predicted to bind. (c) Relative luciferase activity normalized to 
that of cells transfected with an empty control and cells transfected with control 
miRNA. HeyA8 MDR cells were transfected with empty control, wild-type FABP4and 
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then transfected with a control miRNA mimic or a miR-409-3p mimic. **p < 0.01. (d) 
Relative luciferase activity normalized to that of cells transfected with an empty control 
and cells transfected with control miRNA. HeyA8 MDR cells were transfected with 
empty control, wild-type FABP4 (red bar), or FABP4 with mutated 3’UTR (blue bar) 
and then transfected with a control miRNA mimic or a miR-409-3p mimic. Activity was 
measured 48 hours after transfection. *p < 0.05; **p < 0.01; NS indicates not 
significant. (e) Expression of miR-409-3p in various ovarian cancer cell lines 
compared with normal ovarian cells (HIO180). (f) Expression of miR-409-3p in normal 
ovarian tissue and ovarian tumor samples in the GSE15190 dataset. (g) In situ 
hybridization for miR-409-3p (green) and FABP4 (red) in tumor tissues from patients 
with ovarian cancer (n = 8). Representative image is shown.  Effect of miR-409-3p on 
tumor progression. 
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To investigate the effects of miR-409-3p on the metastatic abilities of cells, we 
transfected HeyA8 MDR cells with control miR and miR-409-3p and 48 hours later 
conducted migration and invasion assays. There was a significant reduction in the 
number of cells migrated (p<0.01) and invaded (p<0.01) after miR-409-3p mimic 
transfection (Figure 22 a and b). The effect was consistent in additional cell line and 
Ovcar 5 cells decreased migration (p<0.05) and invasion (p<0.05) after miR-409-3p 
transfection. On the other hand, when transfected with anti-miR-409-3p, there was an 
increase in migration (p<0.05) and invasion of cancer cells (Figure 22 c and d). 
To investigate whether the functions of miR-409-3p are mediated through 
FABP4, we performed a rescue experiment (Figure 22 e). We initially established a 
cell line (SKOV3 ip1) stably overexpressing a FABP4 construct lacking the 3’UTR. 
Thus it would not be sensitive to a miR-409-3p mimic. We conducted luciferase 
experiment as described above. SKOV3ip1 cells with FABP4 were significantly more 
invasive (p < 0.05) compared to the controls. Transfection of the cell line ectopically 
expressing FABP4 with miR-409-3p mimic did not lead to a significant decrease in 
invasion compared to the control miR transfected cells. Thus, we concluded that 
FABP4 could be the main target for  miR-409-3p’s actions related to metastasis 
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Figure 22 (a,b) Effect of miR-409-3p mimic transfection on the (a) invasiveness and 
(b) migration of HeyA8 MDR cells. **p < 0.01. (c,d) Effect of anti-miR-409-3p 
transfection on (c) migration and (d) invasiveness of Ovcar 3 cells. *p < 0.05. (e) 
Invasion potential of SKOV3 ip1 cells was assessed in control cells or cells ectopically 
expressing FABP4 after transfection with control miRNA mimic or miR-409-3p mimic.  
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Having established the tumor suppressive role of miR-409-3p in vitro, we 
examined its effect in vivo. Similar to the previous experiments, we performed intra-
ovarian cell injections of HeyA8 MDR to establish orthotopic mouse model. A week 
after cell injections, mice were intraperitoneally injected with DOPC nanoliposomes 
encapsulating control miR or miR-409-3p mimic twice weekly. At the end of the study, 
mice were sacrificed and tumors were collected, weighed and location of metastases 
were recorded. There was a significant reduction in the tumor burden as well as in the 
number of nodules in the mice treated with miR-409-3p mimic (Figure 23 a and b). In 
the control mice, the metastasis was observed at diaphragm, lymph nodes, pelvis, 
perihepatic and perisplenic areas conversely in the mice treated with miR-409-3p 
mimic the metastasis was mainly localized at ovary and mesentery (figure 23 c). We 
also recorded the mice weight and noticed no harmful effects of the treatment on the 
weight of the mice (figure 23 d).  
We next checked the expression of FABP4 in tumor samples collected from 
mice treated with miR-409-3p mimic. miR-409-3p mimic was able to significantly 
reduce FABP4 expression in the in vivo setting. FABP4 mRNA expression decreased 
after the miR-409-3p mimic injections (p<0.05) (Figure 23 e) but the effect was more 
pronounced at the protein level as seen in western blot and immunohistochemical 
staining (Figure 23 f and g respectively).  
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Figure 23 (a) Aggregate mass of tumors in orthotopic mouse models of ovarian 
cancer (HeyA8 MDR cell line) injected with control miRNA or miR-409-3p mimic 
encapsulated in DOPC liposomes. **p < 0.01. (b) Effect of miR-409-3p mimic on the 
number of nodules. Representative images are shown on the right. **p < 0.01. (c) 
Distribution of tumor nodules in individual mice after treatment with control miRNA or 
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miR-409-3p mimic. (d) The weight of the control and treated mice at the end of the 
experiment. (e) Expression of FABP4 in tumor tissues after treatment with miR-409-
3p mimic treatment. *p < 0.05 (f) Effect of treatment with miR-409-3p mimic on the 
expression of FABP4 (protein) in tumor samples (n = 3). **p < 0.01. (g) Representative 
images of immunohistochemical analysis of FABP4 expression in mice treated with 
control miRNA or miR-409-3p mimic. 
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We next calculated the modified Fagotti scores for the mice in both the groups. Figure 
24 shows the scores for individual mice from the control and miR-409-3p mimic 
groups. Most of the mice from the control group had a score of 8 and above, thus 
indicating increased likelihood of residual disease. On the other hand, mice treated 
with miR-409-3p mimic had scores lower than 8, thus indicating that no residual 
disease is likely to be achieved in these cases. 
 
Figure 24 Modified Fagotti scores for individual mice from control miRNA and miR-
409-3p mimic groups. 
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Chapter 6: Tumor micro-environmental factors regulating FABP4 and miR-409-
3p 
We next decided to explore the tumor micro-environmental factors that can 
affect the expression of miR-409-3p and FABP4. We examined the effect of stromal 
components such as fibroblasts, mesothelial cells, endothelial cells and macrophages 
on cancer cells and also studied the effect of hypoxic conditions on the expression of 
FABP4 in ovarian cancer cells. We incubated cancer cells with the conditioned media 
taken from endothelial fibroblasts, mesothelial cells or macrophages. For hypoxia 
experiments, we subjected cancer cells to 1% hypoxia for 48 hours and collected the 
cells for assessing FABP4 expression. Out of all the factors examined, hypoxia 
consistently increased FABP4 expression in the cancer cells (Figure 25 a). In HeyA8 
MDR cells, hypoxia treatment led to ~3 fold increase in FABP4 level (p<0.05) (Figure 
25 b). The same effect was also observed in an additional cell line, Ovca 432. Hypoxia 
treatment led to ~4 fold increase in FABP4 expression (p<0.05) (Figure 25 c). We then 
decided to check the expression of miR-409-3p in these cells. Interestingly, miR-409-
3p expression was low in the hypoxia-treated cells compared to the control (p<0.05) 
(Figure 25 d). The same effect was also observed in Ovca 432 cells, miR-409-3p 
expression was inhibited by after hypoxia treatment (p<0.05) (Figure 25 e) 
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Figure 25 (a) Effect of tumor micro-environmental factors on the expression of FABP4 
(b c) Effect of hypoxia on (b) FABP4 expression and (c) expression of miR-409-3p in 
HeyA8 MDR cells. (d, e) Effect of hypoxia on (d) miR-409-3p expression and (e) 
FABP4 expression levels in Ovca 432 cells. *p < 0.05.  
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We then decided to see if the similar effects can be seen in vivo. We used the 
tumor samples that are collected from mice treated with bevacizumab. Bevacizumab 
is anti-vascular endothelial growth factor and has been shown to increase hypoxia in 
ovarian cancer patients [91]. We conducted immunohistochemical analysis of the 
tumor sections with CA9 (Carbonic anhydrase 9, a hypoxia marker) and FABP4 
antibodies. We observed consistent co-localization of CA9 and FABP4 in these 
tissues (Figure 26 a). We further used the same samples for qRT-PCR analysis. We 
checked the expression of miR-490-3p in the tumor samples treated with 
bevacizumab and compared it with tumors treated with control antibody. The 
expression of miR-409-3p was lower in the tumors treated with bevacizumab 
compared to the control tumors (Figure 26 b).  
After in vitro and in vivo experiments, we decided the check if the similar 
regulation can be seen in the patient samples. We probed TCGA and Tothill datasets 
for this analysis. We also used the hypoxia metagene signature as described in [84]. 
We extracted the gene expression data for FABP4 and for the genes mentioned in the 
hypoxia metagene signatures.  We saw a positive correlation between FABP4 
expression and the expression of many genes from the signature across various 
platforms. Table 5 shows these correlations. Of particular mention was the gene 
PLAU, plasminogen activator, urokinase. There was a significant correlation between 
FABP4 and PLAU across all the platforms. Figure 26 c shows spearman correlations 
between FABP4 and PLAU. We further checked if silencing of dicer affects the 
expression of miR-409-3p. The qRT-PCR results indicated that knockdown of dicer 
resulted in significant downregulation of miR-409-3p levels (Figure 26 d). Thus in vitro, 
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in vivo and patient data, all point to the regulation of FABP4 and miR-409-3p by 
hypoxia.  
 
Figure 26 (a) Co-localization of CA9 (a hypoxia marker) and FABP4 in tumor tissues 
taken from mice treated with bevacizumab, which is known to induce hypoxia. 
Representative image is shown. (b) miR-409-3p expression levels in tumor tissues 
from mice treated with control vehicle or bevacizumab, which is known to induce 
hypoxia (n = 3 mice per group). (c) Direct correlation of FABP4 with PLAU (a hypoxia 
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signature gene) in patient samples across different platforms. (d) Downregulation of 
miR409-3p after knockdown of dicer (*p<0.05) 
 
 
Table 5 Correlation of FABP4 gene expression with the expression of genes listed in 
Winter hypoxia metagene signature across various data platforms 
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Chapter 7: Downstream effects of FABP4 in cancer cells 
We conducted reverse phase protein array (RPPA) to identify signaling 
pathways regulated by FABP4. We compared two groups- HeyA8 MDR cells 
transfected by control siRNA or by FABP4 siRNA. The heat map is shown in Figure 
27 a. The confirmation of downregulation of FABP4 is presented in the western blot 
(Figure 27 c). Several metastasis related proteins were suppressed in the cells where 
FABP4 expression was silenced (Figure 27 b). We analyzed the RPPA data using 
Ingenuity pathway analysis (IPA) and Netwalker softwares. The results from the IPA 
analysis is presented in Figure 27 d. We noticed that several key pathways related to 
cancer metastasis are downregulated in the cells where FABP4 is inhibited. The 
results from Netwalker analysis also supported this results and revealed that several 
subpathways related to metastasis are significantly downregulated in FABP4 siRNA 
transfected cells (Figure 27 e). 
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Figure 27 (a) RPPA data for downregulated proteins in the FABP4 siRNA and control 
siRNA groups. (b) Proteins that were downregulated in the FABP4 siRNA group are 
related to the metastasis pathway (c) Western blot for confirmation of downregulation 
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of FABP4 in the samples submitted to RPPA (d) Ingenuity pathway analysis of RPPA 
data. (e)  Netwalker analysis of RPPA data. 
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We next sought to identify the metabolomics changes regulated by FABP4. We 
first analyzed the metabolite and gene array presented in [58, 86, 87]. We sorted the 
patient tumor samples based on their expression of FABP4. Samples with FABP4 
expression lower than the median were grouped in ‘Low FABP4’ group while those 
with higher FABP4 expression than the median were grouped in ‘High FABP4’ group. 
We then calculated median expression for each metabolite for samples present in 
each group. Table 6 lists the metabolites that have different expressions depending 
on the expression of FABP4. Low antilog value indicates low expression in low FABP4 
group. We saw that several metabolites are different in high versus low FABP4 
groups. 
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BIOCHEMICAL NAME Antilog
glutathione, reduced (GSH) 0.01906
N-acetylaspartate (NAA) 0.15397
glycerophosphorylcholine (GPC) 0.27502
glycerol 3-phosphate (G3P) 0.30117
ascorbate (Vitamin C) 0.31861
N-acetyl-aspartyl-glutamate-NAAG- 0.49411
glucose 6-phosphate (G6P) 0.51071
glutathione, oxidized (GSSG) 0.54313
fructose-6-phosphate 0.56294
1-palmitoylglycerophosphoethanolamine 0.5662
adenosine-3-monophosphate-3 (AMP) 0.57108
dehydroascorbate 0.57873
obar-ribulose-5-phosphate-xylulose-5-phospha 0.5815
1-arachidonoylglycerophosphoinositol- 0.58669
2-oleoylglycerophosphoethanolamine- 0.59617
glycerol 2-phosphate 0.60175
1-palmitoylplasmenylethanolamine- 0.61374
1-oleoylglycerophosphoethanolamine 0.61412
dihydroxyacetone-phosphate-DHAP- 0.61641
S-adenosylhomocysteine (SAH) 0.62201
p-cresol-sulfate 0.67683
phosphoenolpyruvate (PEP) 0.67818
mannose-6-phosphate 0.68185
1-palmitoylglycerophosphoinositol- 0.68692
2-hydroxystearate 0.70347
carnitine 0.70723
gluconate 0.73625
2-hydroxypalmitate 0.73722
choline-phosphate 0.73992
1-stearoylglycerophosphoethanolamine 0.74021
butyrylcarnitine 0.74046
docosahexaenoate (DHA; 22:6n3) 0.74079
behenate-22-0- 0.74804
2-phosphoglycerate 0.75226
7-alpha-hydroxy-3-oxo-4-cholestenoate-7-Hoca 0.75483
4-hydroxybutyrate-GHB- 0.7568
2-hydroxyglutarate 0.76382
xylulose 0.77906
erythronate* 0.78137
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1-linoleoylglycerophosphoethanolamine- 0.78458
propionylcarnitine 0.78633
ribitol 0.78647
1-stearoylglycerophosphoinositol 0.78654
inosine 0.78697
6-phosphogluconate 0.78916
dihomo-linolenate-20-3n3-or-n6- 0.79142
adrenate (22:4n6) 0.79299
arachidonate (20:4n6) 0.79409
docosapentaenoate-n6-DPA-22-5n6- 0.79532
ribose 0.79596
1,3-dihydroxyacetone 0.79703
phenylacetylglutamine 0.81738
3-phosphoglycerate 0.81998
spermidine 0.82124
alpha-hydroxyisovalerate 0.8232
bilirubin*E-E- 0.82466
adenosine-2-monophosphate-2 (AMP) 0.82958
isobutyrylcarnitine 0.83273
gamma-glutamylglutamate 0.83707
1-oleoylglycerophosphoinositol- 0.83845
isovalerylcarnitine 0.8385
pyruvate 0.84004
palmitoyl-sphingomyelin 0.84332
ophthalmate 0.84399
arabitol 0.8462
4-androsten-3beta-17beta-diol-disulfate-1- 0.85172
guanosine 0.85421
malate 0.85855
3-(4-hydroxyphenyl)lactate 0.86185
succinylcarnitine 0.86332
3-aminoisobutyrate 0.86378
fumarate 0.86417
flavin adenine dinucleotide (FAD+) 0.86571
1-arachidonoylglycerophosphoethanolamine- 0.86664
2-hydroxybutyrate (AHB) 0.87137
pantothenate 0.8716
eicosapentaenoate (EPA; 20:5n3) 0.87434
beta-hydroxyisovalerate 0.87622
caproate (6:0) 0.87751
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glycylglycine 0.8796
cholesterol 0.8799
undecanedioate 0.88118
glycerate 0.88232
N1-methyladenosine 0.88694
2-aminobutyrate 0.8875
inositol-1-phosphate (I1P) 0.88849
uridine 0.88874
pyroglutamine* 0.88912
pregnen-diol-disulfate- 0.89145
nicotinamide 0.89562
choline 0.89575
glutamine 0.89829
alanine 0.90003
cytidine 5'-monophosphate-5-CMP- 0.90154
cysteine-glutathione-disulfide 0.90385
threonine 0.90621
hypoxanthine 0.90661
xanthosine 0.90721
xanthine 0.90767
acetylphosphate 0.9186
pyrosphosphate (PPi) 0.92256
leucine 0.92607
isoleucine 0.92645
cystathionine 0.92675
myo-inositol 0.9276
kynurenine 0.93418
hippurate 0.93739
urea 0.9379
heptaethylene-glycol 0.93795
methionine 0.93892
gamma-glutamylleucine 0.94026
acetylcarnitine 0.94029
creatine 0.94166
fructose 0.94302
glutamate 0.94468
N-formylmethionine 0.94594
tryptophan-betaine- 0.94846
5-oxoproline 0.95119
glycine 0.95285
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azelate (nonanedioate) 0.95372
docosatrienoate-22-3n3- 0.95406
N-acetylglycine 0.95473
proline 0.95505
phenylalanine 0.95584
histidine 0.95635
aspartate 0.95794
pipecolate 0.95885
N-acetylneuraminate 0.95938
serine 0.95978
1,5-anhydroglucitol (1,5-AG) 0.96095
valine 0.9626
glycolate (hydroxyacetate) 0.96378
C-glycosyltryptophan- 0.9671
mannose 0.9691
mannitol 0.97312
3-dehydrocarnitine* 0.97348
2-aminoadipate 0.97574
gamma-glutamylphenylalanine 0.97589
stearate (18:0) 0.9774
ribulose 0.97766
5,6-dihydrouracil 0.98053
pelargonate (9:0) 0.98125
gamma-glutamylglutamine 0.9821
tyrosine 0.98455
putrescine 0.98462
lactate 0.98478
uracil 0.98781
phosphoethanolamine 0.98814
erythritol 0.99101
urate 0.99101
hexaethylene-glycol 0.9922
N-acetylserine 0.99228
ornithine 0.99386
phosphate 0.99474
sorbitol 0.99577
ribose-5-phosphate 0.99604
cystine 0.99679
caprylate (8:0) 0.99829
margarate (17:0) 0.9988
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rboxy-4-methyl-5-propyl-2-furanpropanoate (CM 1
biliverdin 1
tetradecanedioate 1
ethanolamine 1.00054
asparagine 1.0009
myristate (14:0) 1.00993
hydroxyisovaleroyl-carnitine 1.01115
N-acetylthreonine 1.01121
palmitoyl-ethanolamide 1.01534
taurine 1.01649
gamma-aminobutyrate (GABA) 1.01724
arginine 1.01765
N6-acetyllysine 1.01896
laurate (12:0) 1.01939
creatinine 1.02247
N-acetylalanine 1.02297
hypotaurine 1.02305
assymetric-dimethylarginine (ADMA) 1.02316
nonadecanoate (19:0) 1.02736
methylphosphate 1.0274
tryptophan 1.0274
docosadienoate-22-2n6- 1.03034
myristoleate (14:1n5) 1.03036
lysine 1.03382
argininosuccinate 1.03817
glycerol 1.03922
cysteine 1.03926
ergothioneine 1.04088
caprate (10:0) 1.04506
trans-4-hydroxyproline 1.0482
scyllo-inositol 1.04943
eicosenoate (20:1n9 or 11) 1.0505
riboflavin (Vitamin B2) 1.05709
gamma-glutamylvaline 1.05969
fructose-1-phosphate 1.06182
3-hydroxybutyrate (BHBA) 1.06391
palmitate (16:0) 1.06449
docosapentaenoate (n3-DPA; 22:5n3) 1.06805
maltose 1.0704
dihomo-linoleate-20-2n6- 1.07442
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N-acetylmethionine 1.07588
N-acetylornithine 1.08646
15-HETE 1.09975
citrate 1.11086
pseudouridine 1.11583
stearidonate (18:4n3) 1.11806
5-methylpalmitate-isobar-with-2-methylpalmitat 1.11878
pentadecanoate (15:0) 1.12253
beta-alanine 1.12512
13-HODE-9-HODE 1.12574
cortisol 1.12874
3-methyl-2-oxovalerate 1.12939
succinate 1.13281
oleate (18:1n9) 1.13819
4-methyl-2-oxopentanoate 1.15256
2-linoleoylglycerophosphoethanolamine- 1.15983
N-acetylglucosamine-6-phosphate 1.1648
betaine 1.17065
glucose 1.17257
alpha-tocopherol 1.174
octadecanedioate 1.18455
linoleate (18:2n6) 1.19287
hosphate-glucose-1,6-diphosphate-myo-inosito 1.19868
phenol sulfate 1.2092
10-nonadecenoate (19:1n9) 1.22548
guanine 1.23592
hexadecanedioate 1.23857
linolenate [alpha or gamma] (18:3n3 or 6) 1.25673
palmitoleate (16:1n7) 1.26189
1-2-propanediol 1.26983
threonate 1.27318
maltotriose 1.30167
17-methylstearate 1.35496
stachydrine 1.38221
10-heptaadecenoate (17:1n7) 1.38914
1-stearoylglycerophosphocholine 1.4357
maltotetraose 1.63675
-docosahexaenoylglycerophosphoethanolamine1.67267
2-arachidonoylglycerophosphocholine* 1.75107
1-palmitoylglycerophosphocholine 2.54398
2-arachidonoylglycerophosphoethanolamine- 6.09392
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Table 6 Metabolites differentially expressed in patient samples belonging to low- and 
high-FABP4-expression groups. Lower antilog value represents lower expression in 
the low-FABP4 group. 
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One of the limitations of this analysis was that the gene and metabolites arrays 
were conducted on the entire tumor tissues.  Thus, the data could have been 
influenced by the genes or metabolites present in the stromal cells. To address this 
concern, we used Desorption Electrospray Ionization-Mass Spectrometry (DESI-MS 
imaging) technique. The technique not only identifies metabolites present in a tissue 
but gives the spatial information of the metabolite as well. For this experiment, we 
used the chemotherapy naïve, high grade ovarian tumor samples used in our initial 
biomarker discovery study. Based on their FABP4 expression, top 25% tumor samples 
were classified in ‘high FABP4’ group while the rest of the samples were classified in 
‘Low FABP4’ group. We then conducted DESI-MS imaging in both, negative and 
positive polarities on 31 tumor samples.  
The first step in the analysis was to check if there are sufficient differences in 
the metabolites and lipids that can correlate with the changes in FABP4 expression. 
Lasso (Least absolute shrinkage and selector operator) method was used to explore 
the correlations between lipids, metabolites and FABP4 levels. The samples were 
divided into training and validation groups. First, the training set was used to build a 
molecular model. The coefficient of variation analysis on the negative ion mode data 
from the training set, showed an overall agreement of 81.6%. The area under curve 
(AUC) was 0.79. The result thus suggested an association between the expression 
and composition of metabolites, and the expression of FABP4 in ovarian tumor 
tissues. The model generated from the training set was used for the samples from the 
validation set. When the negative ion mode data for the validation set was analyzed, 
the overall agreement of was found to be 51.6% and AUC was 0.60 (Table 7 a). Similar 
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methods were used for to analyze the positive ion mode data. The overall agreement 
for the training set was 74.2% with AUC=0.73 while the validation set yielded the 
overall agreement of 61.7% and AUC of 0.58 (Table 7 b). Thus, in both positive as 
well as in negative ion mode, the results indicate an association between metabolites 
and FABP4 expression. 
We then decided to investigate if FABP4 levels can be predicted from the 
metabolite information (Table 7). We combined positive and negative ion mode data 
and built a comprehensive model. The data was then analyzed for each patient by 
cross-validation method. The analysis successfully classified 66.7% of high FABP4 
samples and 100% of low samples in the right categories. Molecular models based 
on the lipid and metabolite data thus established that FABP4 expression can alter 
metabolic profiles of ovarian cancer tissues.
 
 
Table 7 (a) Model correlating molecular profiles and FABP4 expression based on 
negative ion mode data 
(b) Model correlating molecular profiles and FABP4 expression based on 
positive ion mode data   
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The next step was to identify the metabolites that are altered by FABP4 
expression. We hence analyzed the data by SAM (Significant analysis of Microarray) 
method and identified m/z values (mass to charge ratios) of the metabolites that differ 
in their expression in low and high FABP4 groups. With the false discovery rate of 
3.8%, we were able to identify 122 unique monoisotonic m/z values characteristic of 
low FABP4 expression and 118 values characteristic of high FABP4 expression. We 
then used high mass accuracy/high mass resolution and tandem mass spectrometry 
analysis to identify the metabolite species associated with the m/z values. The species 
identified belong to the following classes of metabolites- small metabolites, fatty acids 
(FA), sterol lipids (ST), ceramides (Cer), glycerolipids (GL), 
monoacylglycerophosphates (PA), glycerophosphoethanolamines (PE), 
glycerophosphoglycerols (PG), glycerophosphoinositols (PI), glycerophosphoserines 
(PS), and cardiolipins (CL). 
There were several metabolites that were uniquely different in both the groups. 
Table 8 and 9 lists all the metabolites present in low and high FABP4 groups. The 
composition of fatty acids was significantly different in low vs. high FABP4 groups. An 
increased number of highly unsaturated fatty acids was observed in high FABP4. 
Oxidation of fatty acids was also specifically observed in high FABP4 group. 
Glycerolipids, glycerophosphoethanolamines, glycerophosphoglycerols and 
lysophospholipid species, including LysoPE, LysoPG, and LysoPI were abundantly 
present in high FABP4 group compared to low FABP4 group. Conversely, the number 
of non-oxidized glycerophosphoinositols and glycerophosphoserines species was 
higher in the low FABP4 samples compared to the high FABP4 group and cardiolipins 
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were exclusively present in the low FABP4 samples. These observations suggest that 
changes in the metabolic profiles of ovarian cancer tissues are associated with 
variations in FABP4 expression.  
HUMAN SAMPLES - HIGH FABP4 EXPRESSION 
Attribution  Molecular Formula  Detected m/z  
Mass error 
(ppm) 
SAM 
Score 
Metabolites        
N-acetylaspartic acid C6H8NO5 174.0408 0.0 -17.207 
Ascorbic acid  C6H7O6 175.0252 2.3 -5.943 
Gluconic acid  C6H11O7 195.0509 0.5 -41.91 
Phosphatidic acid C6H8O7Cl 226.9962 0.9 -6.776 
Fatty Acids          
FA 14:1  C14H25O2 225.1862 -0.9 -23.744 
FA 17:0 C17H33O2 269.2484 0.7 -0.514 
FA hydroxy 16:0 C16H31O3 271.2279 0.4 -13.784 
FA 18:3 C18H29O2 277.2171 0.7 -4.145 
FA 18:2 C18H31O2 279.2327 1.1 -11.127 
FA 18:1 C18H32O2 281.2484 0.7 -5.365 
FA 18:0 C18H35O2 283.2640 1.1 -3.589 
FA 20:5 C20H29O2 301.2171 0.7 -12.165 
FA 20:4 C20H31O2 303.2327 1.0 -27.378 
FA 18:2 C18H32O2Cl 315.2092 1.3 -17.244 
FA 18:1 C18H34O2Cl 317.2249 1.3 -21.336 
FA hydroxy 20:4  C20H31O3 319.2284 -1.6 -18.929 
FA 18:0 C18H36O2Cl 319.2407 0.6 -22.176 
FA hydroxy 20:3  C20H33O3 321.2427 2.5 -8.559 
FA 22:6 C22H31O2 327.2326 1.2 -21.309 
FA 22:5 C22H33O2 329.2482 1.2 -22.572 
FA 22:4 C22H35O2 331.2639 1.2 -37.569 
FA 22:3 C22H37O2 333.2794 1.5 -6.211 
FA 20:4 C20H32O2Cl 339.2093 0.9 -32.242 
FA hydroxy 22:6  C22H31O3 343.2296 -5.0 -5.971 
FA 24:5 C24H37O2 357.2795 1.1 -16.621 
FA 24:4 C24H39O2 359.2953 0.8 -17.472 
FA 24:3 C24H41O2 361.3106 1.7 -0.934 
FA 22:4 C22H36O2Cl 367.2416 -1.9 -33.351 
FA hydroxy 24:0  C24H47O3 383.3526 1.3 -2.796 
Glycerolipids         
MG 18:0 C21H40O4Cl 391.2615 1.5 -7.537 
MG 22:6 C25H38O4Cl 437.2459 1.1 -6.813 
DG 32:1/0:0 C35H66O5Cl 601.4594 1.7 -8.245 
DG 32:0/0:0 C35H68O5Cl 603.4758 0.5 -3.515 
DG 34:3/0:0 C37H66O5Cl 625.4594 1.6 -2.261 
DG 34:2/0:0 C37H68O5Cl 627.4754 1.1 -6.743 
DG 34:1/0:0 C37H70O5Cl 629.4913 0.6 -14.24 
DG 36:4/0:0 C39H68O5Cl 651.4753 1.2 -13.268 
DG 36:3/0:0 C39H70O5Cl 653.4916 0.2 -4.762 
DG 36:2/0:0 C39H72O5Cl 655.5072 0.3 -15.714 
DG 38:6/0:0 C41H68O5Cl 675.4752 1.3 -18.92 
DG 38:5/0:0 C41H70O5Cl 677.4932 -2.2 -15.97 
DG 38:4/0:0 C41H72O5Cl 679.5089 -2.2 -15.44 
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DG 40:7/0:0 C43H70O5Cl 701.4892 3.6 -2.8 
DG 40:6/0:0 C43H72O5Cl 703.5063 1.6 -15.599 
DG 40:5/0:0 C43H74O5Cl 705.5230 1.1 -15.089 
Glycerophosphoethanolamines       
LysoPE P-16:0 C21H43NO6P 436.2843 -2.3 -3.539 
LysoPE O-18:1 C23H47NO6P 464.3159 -2.8 -30.415 
LysoPE 18:1 C23H45NO7P 478.2951 -2.5 -4.209 
LysoPE 18:0 C23H47NO7P 480.3109 -2.7 -5.842 
LysoPE 20:4 C23H43NO7P 500.2796 -2.6 -18.64 
PE 20:4/1:0 C26H43NO8P 528.2728 -0.8 -36.177 
PE 34:0 C23H47NO6P 718.5378 1.9 -0.697 
PE P-18:0/18:4 C41H73NO7Cl 722.5116 1.9 -10.493 
PE O-38:5 or PE P-38:4 C43H77NO7P 750.5432 -1.2 -35.708 
PE 38:5 C43H75NO8P 764.5224 -3.2 -24.395 
PE 38:4 C43H77NO8P 766.5382 6.2 -6.357 
PE 38:2 C43H81NO8P 770.5657 1.2 -4.115 
PE 38:1 C43H83NO8P 772.5853 1.9 -19.182 
PE 39:6 C44H75NO8P 776.5221 1.8 -17.599 
PE 39:5 C44H77NO8P 778.5378 -1.0 -17.599 
PE O-40:5 or PE P-40:4 C45H81NO7P 778.5764 0.5 -20.071 
PE 40:5 C45H79NO8P 792.5545 -1.6 -10.169 
PE 37:1 C42H82NO8PCl 794.5485 -0.8 -4.871 
PE 40:4 C45H81NO8P 794.5711 0.7 -20.835 
PE 39:4 C44H80NO8PCl 816.5310 0.7 -4.447 
PE 39:2 C44H84NO8PCl 820.5623 2.9 -12.74 
PE 39:1 C44H86NO8PCl 822.5761 -4.0 -16.628 
PE 41:6 C46H80NO8PCl 840.5350 -2.7 -14.693 
PE 41:5 C46H82NO8PCl 842.5495 1.1 -26.422 
PE 41:4 C46H84NO8PCl 844.5620 -1.4 -25.036 
PE 43:6 C48H84NO8PCl 868.5641 -3.4 -7.314 
PE 43:2 C48H92NO8PCl 876.6285 0.8 -8.158 
Glycerophosphoglycerols        
LysoPG 16:0 C22H44O9P 483.2734 -2.1 -7.141 
LysoPG 18:2 C24H44O9P 507.2744 -3.1 -20.225 
LysoPG 18:1 C24H46O9P 509.2881 -2.9 -18.358 
LysoPG 22:6 C28H44O9P 555.2744 -0.7 -11.491 
PG 34:3 C40H72O10P 743.4890 -2.8 -0.683 
PG 34:2 C40H74O10P 745.5015 1.5 -1.249 
PG 16:0/18:1 C40H76O10P 747.5196 1.6 -4.319 
PG 36:4 C42H74O10P 769.5007 2.3 -18.539 
PG 18:2/18:1 C42H76O10P 771.5201 -2.5 -4.819 
PG 18:1/18:1 C42H78O10P 773.5331 0.9 -2.341 
PG 38:6 C44H74O10P 793.5010 1.9 -7.587 
PG 38:5 C44H76O10P 795.5145 4.7 -2.768 
PG 40:8 C46H74O10P 817.5011 1.7 -6.187 
PG 40:7 C46H76O10P 819.5160 2.7 -2.822 
PG 40:6 C46H78O10P 821.5309 3.5 -0.714 
PG 40:5 C46H80O10P 823.5480 1.8 -0.707 
PG 22:6/22:6 C50H74O10P 865.4996 3.4 -7.994 
Ceramides         
Cer d32:1 C32H63NO3Cl 544.4519 0.9 -8.899 
Cer d16:1/17:0 C33H65NO3Cl 558.4663 0.7 -16.215 
Cer d34:2 C34H65NO3Cl 570.4655 1.8 -8.47 
Cer d34:1 C34H67NO3Cl 572.4809 0.5 -1.065 
Cer d36:2 C36H69NO3Cl 598.4960 -1.7 -4.673 
Cer d36:1 C36H71NO3Cl 600.5118 -2.4 -17.626 
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Cer d38:1  C40H79NO3Cl 656.5752 -0.1 -8.174 
Cer d41:2 C41H79NO3Cl 668.5766 -0.4 -1.288 
Cer d42:0  C42H81NO3Cl 682.5901 1.3 -0.513 
Cer d42:1 C42H83NO3Cl 684.6068 1.0 -1.236 
PE-Cer d36:1 C38H76N2O6P 687.5449 -0.4 -4.101 
Monoacylglycerophosphates        
PA 36:1 C39H74O8P 701.5120 1.0 -18.155 
PA O-38:2 or PA P-38:1 C41H79O7PCl 749.5278 1.3 -11.93 
Cardiolipins         
CL 72:4 C81H148O17P2 727.5070 -1.9 -7.459 
Glycerophosphoinositols        
LysoPI 15:0 C24H46O12P 557.2729 0.5 -16.255 
LysoPI O-16:0 C25H50O11P 557.3091 0.9 -5.78 
LysoPI 18:0 C27H52O12P 599.3199 0.5 -20.061 
Lyso PI 20:4 C29H48O12P 619.2904 -2.4 -15.733 
PI O-33:2 or PI P-33:1  C42H79O12PCl 841.5011 -1.0 -13.023 
PI P-18:0/17:2 C44H81O12PCl 867.5158 0.2 -15.209 
PI O-35:2 or PI P-35:1 C44H83O12PCl 869.5312 0.5 -1.013 
PI 37:4 C46H80O13P 871.5342 3.3 -3.616 
PI 38:6 C47H78O13P 881.5159 3.1 -15.606 
PI 38:5 C47H80O13P 883.5332 1.1 -15.194 
PI 38:4 C47H82O13P 885.5483 1.8 -27.615 
PI 40:4 C49H86O13P 913.5793 2.1 -18.087 
PI 40:3 C49H88O13P 915.5952 1.7 -8.514 
Glycerophosphoserines        
PS O-36:4 or PS P-36:3 C42H75NO9P 768.5211 -3.4 -6.698 
PS 38:4 C44H77O10NP 810.5279 1.5 -0.461 
PS O-39:0 C45H89NO9P  818.6245 4.3 -0.518 
PS O-40:4 or PS P-40:3 C46H83NO9P 824.5810 0.1 -12.284 
PS 39:2 C45H83NO10P 828.5724 4.3 -4.851 
 
Table 8. High FABP4– human data – 122 m/z values  
 
HUMAN SAMPLES - LOW FABP4 EXPRESSION 
Attribution  Molecular Formula  Detected m/z  
Mass error 
(ppm) 
SAM 
Score 
Metabolites        
Fumarate C47H84O13P 115.0039 -1.7 18.081 
Acetyl-glycine  C4H6NO3 116.0351 1.7 11.101 
Succinate  C4H5O4 117.0195 -1.7 31.003 
2-Hydroxy-3-methylbutyric 
acid  C5H9O3 117.0559 -1.7 19.079 
Taurine  C2H6NO3S 124.008 -0.8 27.304 
Pyroglutamate C5H6NO3 128.0355 -1.6 8.295 
Aspartate C4H6NO4 132.0305 -2.3 18.919 
3-Hydroxypicolinic acid C6H4NO3 138.0198 -0.7 40.807 
Glutamine  C5H9N2O3 145.0621 -1.4 20.826 
Glutamic acid  C5H8NO4 146.0460 0.7 26.925 
2-Hydroxyglutarate  C5H7O5 147.0302 -2.0 21.018 
Xanthine C5H3N4O2 151.0263 -1.3 37.65 
Glycerophosphoglycerol  C6H14O8P 245.0430 -0.8 18.354 
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Glutathione  C10H82N3O6S 306.0762 2.6 42.764 
Fatty Acids          
FA 8:0 C8H15O2 143.1079 0.7 29.669 
FA 9:0 C9H17O2 157.1235 -0.6 29.847 
FA 15:0 C15H29O2 241.2183 4.1 4.87 
FA 16:1 C16H29O2 253.2171 -0.8 3.483 
FA 20:3 C20H33O2 305.2483 -1.0 15.075 
FA 20:2 C20H35O2 307.2638 -1.6 11.185 
FA 20:1 C20H37O2 309.2795 2.3 20.186 
FA 20:0 C20H39O2 311.2952 -1.3 8.804 
FA 22:0 C22H43O2 339.3264 1.5 10.756 
FA 23:1 C23H43O2 351.3261 2.3 11.157 
FA 23:0 C23H45O2 353.3420 1.4 7.575 
FA 24:1 C24H45O2 365.3420 1.4 21.275 
FA 24:0 C24H47O2 367.3578 1.1 21.739 
FA 26:3 C26H45O2 389.3422 0.8 11.355 
FA 26:2 C26H47O2 391.3578 1.0 17.688 
FA 26:1 C26H49O5 393.3734 1.0 11.657 
FA 26:0 C26H51O2 395.3889 1.5 29.87 
Glycerolipids         
DG 24:0/0:0 C27H51O5 455.3760 4.0 10.533 
Glycerophosphoethanolamines        
PE 18:1/1:0 C24H45NO8P 506.2882 1.2 11.03 
PE 20:3/1:0 C26H45NO8P 530.2912 -4.5 21.256 
PE O-34:3 or PE P-34:2 C39H73NO7P 698.5153 3.3 23.028 
PE O-34:2 or PE P-34:1  C39H75NO7P 700.5272 2.1 21.527 
PE 34:2 C39H73NO8P 714.5052 3.8 25.328 
PE 34:1 C39H75NO8P 716.5221 2.1 21.369 
PE O-36:3 or P-36:2 C41H77NO7P 726.5449 0.8 15.769 
PE 35:1 C40H77NO8P 730.5368 3.3 9.588 
PE 36:3 C41H75NO8P 740.5208 3.8 27.408 
PE 36:2 C41H77NO8P 742.5378 1.9 18.265 
PE 38:3 C43H79NO8P 768.5574 -3.3 27.714 
Glycerophosphoglycerols        
PG 18:0/18:1 C42H80O10P 775.5482 1.7 19.923 
PG 18:0/18:0 C42H82O10P 777.5651 0.3 13.591 
PG 38:4 C44H78O10P 797.5313 3.1 6.512 
PG 38:3 C44H80O10P 799.5467 3.5 13.973 
PG 38:2 C44H82O10P 801.5634 2.1 12.159 
PG 42:7 C48H80O10P 847.5463 3.8 9.462 
Ceramides         
Cer d18:16:0 C34H69NO3Cl 574.4962 1.6 13.104 
Cer m18:1/22:0 C40H79NO2Cl 640.5796 1.4 7.264 
Cer m18:1/24:1 C42H81NO2Cl 666.5975 2.1 20.026 
Cer m42:1 C42H83NO2Cl 668.6109 1.3 16.913 
Cer d18:1/23:0 C41H81NO2Cl 670.5895 2.4 5.698 
Cer d40:0(2OH) C40H81NO4Cl 674.5874 -2.1 16.897 
Cer d42:1 C42H83NO3Cl 684.6068 0.1 10.001 
Cer d42:0 C42H85NO3Cl 686.6221 0.3 21.885 
Cer d18:1/25:0 C43H85NO3Cl 698.6223 0.3 11.719 
Cer d18:1/26:1 C44H85NO3Cl 710.6258 4.9 11.435 
Cer d18:1/26:0 C44H87NO3Cl 712.6369 1.5 6.835 
PE - Cer 36:3 C38H73N2O6PCl 719.4881 2.6 11.341 
GlcCer d34:1 C40H77NO8Cl 734.5323 2.7 5.86 
PE-Cer d37:1 C39H79N2O6PCl 737.5359 1.5 14.674 
Monoacylglycerophosphates       
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PA 32:0 C35H68O8P 647.4678 3.2 17.343 
PA 24:2 C37H68O8P 671.4642 2.2 17.925 
PA 24:1 C37H70O8P 673.4814 1.6 22.269 
PA 36:4 C39H68O8P 695.4646 1.6 11.851 
PA 36:3 C39H70O8P 697.4801 1.9 12.823 
Cardiolipins         
CL 68:5 C77H138O17P2 698.4716 0.9 5.183 
CL 70:7 C79H138O17P2 710.4697 1.8 25.307 
CL 70:6 C79H140O17P2 711.4767 3.0 20.886 
CL 70:5 C79H142O17P2 712.4837 4.2 11.261 
CL 72:8 C81H140O17P2 723.4791 0.4 20.666 
CL 72:7 C81H142O17P2 724.4841 3.6 26.85 
CL 72:6 C81H144O17P2 725.4941 0.6 25.978 
CL 74:10 C83H140O17P2 735.4779 1.2 13.261 
CL 74:9 C83H142O17P2 736.4852 2.0 22.139 
CL 74:8 C83H144O17P2 737.4921 3.3 22.478 
CL 74:7 C83H146O17P2 738.5015 1.1 18.876 
CL 76:10 C85H144O17P2 749.4924 2.8 19.881 
CL 76:9 C85H146O17P2 750.5045 2.9 15.033 
CL 76:8 C85H148O17P2 751.5086 2.0 14.259 
CL 76:7 C85H150O17P2 752.5161 2.5 13.432 
CL 36:4 C45H82O15P2Cl 959.4823 2.4 2.809 
Glycerophosphoinositols        
LysoPI (16:0/0:0) C25H48O12P 571.2899 1.8 4.408 
PI (32:1) C41H76O13P 807.5016 1.6 22.334 
PI (32:0) C41H78O13P 809.5141 5.6 25.352 
PI (34:2) C43H78O13P 833.5166 2.4 28.065 
PI (34:1) C43H80O13P 835.5321 2.5 25.546 
PI (O-23:0) C42H83O12PCl 845.5318 0.2 7.793 
PI (25:1) C44H82O13P 849.5519 -2.4 21.476 
PI (36:4) C45H78O13P 857.5172 1.6 2.918 
PI (36:3) C45H80O13P 859.5347 -0.6 31.721 
PI (36:2) C45H82O13P 861.5486 1.5 45.539 
PI (36:1) C45H84O13P 863.5655 2.8 25.679 
PI (37:3) C46H82O13P 873.5506 -0.8 17.932 
PI (38:6) C47H78O13P 881.5196 1.1 20.554 
PI (38:3) C47H84O13P 887.5653 -0.2 18.707 
PI (40:6) C49H82O13P 909.5472 -3.0 9.853 
PI (39:4) C48H85O13PCl 935.5441 2.0 20.006 
C13 PI (40:7) C49H81O13PCl 943.5110 0.1 9.499 
Glycerophosphoserines       
PS P-34:1 C40H75NO9P 744.5177 1.1 4.274 
PS 16:0/18:1 C40H75NO10P 760.5149 2.0 18.59 
PS P-36:2 or PS O-36:3 C42H77NO9P 770.5324 2.2 14.362 
PS O-36:2 or PS P-36:1 C42H79NO9P 772.5490 1.0 4.287 
PS 36:3 C42H75NO10P 784.5133 0.1 28.208 
PS 36:2 C42H77NO10P 786.5279 1.5 34.307 
PS 18:0/18:1 C42H79NO10P 788.5466 -2.4 17.526 
PS O-38:4 or P-38:3 C44H79NO9P 796.5467 3.9 4.253 
PS 38:3 C44H79NO10P 812.5437 1.2 31.901 
PS 38:2 C44H81NO10P 814.5577 3.3 30.261 
PS 38:1 C44H83O10NP 816.5745 1.8 23.544 
PS 40:6 C46H77O10NP 834.5271 2.4 13.286 
PS 40:2 C46H85O10NP 842.5906 1.3 17.723 
PS 40:1 C46H87O10NP 844.6056 2.0 21.329 
PS 42:3 C48H87O10NP 868.6029 -5.1 15.417 
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PS 42:2 C48H89O10NP 870.6220 -1.1 17.786 
PS 42:1 C48H91O10NP 872.6369 -1.9 20.275 
 
Table 9. Low FABP4 – human data 118 m/z values  
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For our next step of analysis, we decided to conduct DESI-MS imaging on in 
vivo tumor tissues from one of our experiments. The two groups that we selected 
were- Control siRNA and FABP4 siRNA. The metabolite profiles of these tissues 
would be a direct result of the changes in FABP4 expression and hence is crucial to 
understand how knocking down FABP4 can affect the metabolomics of cancer cells. 
The primary results from these analyses are presented in Figure 28 and the detailed 
analysis is presented in Table 10 and 11. There were 125 metabolites that were 
unique to the control siRNA group while 59 metabolites were only present in the 
FABP4 siRNA group. Similar to the patient analysis, we noticed more fatty acids and 
glycerolipids in control siRNA (i.e. high FABP4 group) than FABP4 siRNA group (i.e. 
Low FABP4 group). There was an enrichment of unsaturated and oxidated fatty acids 
and lysophospholipids species in the control siRNA group. Interestingly we did not see 
any fatty acid in FABP4 siRNA treated group. There were 50 metabolites that were 
common between mice and human data when high FABP4 was considered while 26 
species were found to be common in mice and human samples when low FABP4 data 
was considered (Table 12 and 13). 
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Figure 28 DESI-MS imaging pictures of in vivo tumor tissues. Representative pictures 
show metabolites like glycerophosphoinositols (PI), glycerophosphoserines (PS), 
glycerophosphoethanolamines (PE), glycerophosphoglycerols (PG) and fatty acids 
(FA) are suppressed after FABP4 is knocked down with FABP4 siRNA. On the other 
hand, ceramides are present in more abundance in FABP4 siRNA group compared to 
the control group.  
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MICE SAMPLES - CONTROL - HIGH FABP4 EXPRESSION 
Attribution  Molecular Formula  
Detected 
m/z  
Mass error 
(ppm) 
SAM 
Score 
Metabolites      
Uracil C4H3O2N2 111.0199 0.9 -7.573 
Taurine  C2H6NO3S 124.0073 0.8 -5.756 
Xanthine C5H3O2N4 151.0260 -0.7 -6.716 
Ascorbic acid  C6H7O6 175.0245 -1.7 -2.442 
Citrate C6H7O7 191.0193 -2.1 -9.995 
Lauric Acid C12H23O2 199.1699 -2.5 -10.98 
Glycerophosphoethanolamine C5H13NO6P 214.0481 -2.3 -12.602 
Glucose C6H12O6Cl 215.0323 -2.3 -4.518 
Norselic acid A C29H39O2 451.2859 -1.1 -11.045 
Fatty Acids     
FA 8:0 C8H15O2 143.1076 -1.4 -10.212 
FA 14:0 C14H27O2 227.2011 -2.6 -15.768 
FA 15:0  C15H29O2 241.2166 -2.9 -13.172 
FA 16:2 C16H27O2 251.2008 -3.6 -9.152 
FA 16:1 C16H29O2 253.2167 -2.4 -16.69 
FA 16:0 C16H31O2 255.2324 -2.4 -22.387 
FA 18:3 C18H29O2 277.2167 -2.2 -14.723 
FA 18:2 C18H31O2 279.2324 -2.1 -22.826 
FA 18:1 C18H33O2 281.2480 -2.1 -22.745 
FA 18:0 C18H35O2 283.2636 -2.1 -21.869 
FA hydroxy 18:2 C18H31O3 295.2271 -2.7 -8.968 
FA 19:1 C19H35O2 295.2635 -2.7 -19.208 
FA 19:0 C19H37O2 297.2792 -2.4 -16.768 
FA 20:5 C20H29O2 301.2165 2.7 -7.552 
FA 20:4 C20H31O2 303.2322 2.6 -22.184 
FA 20:3 C20H33O2 305.2477 2.9 -20.094 
FA 20:2 C20H35O2 307.2634 2.9 -21.457 
FA 20:1 C20H37O2 309.2791 2.6 -21.247 
FA 20:0 C20H39O2 311.2946 3.2 -15.449 
FA 18:2 C18H32O2Cl 315.2087 2.9 -6.647 
FA 18:1  C18H34O2Cl 317.2245 2.5 -6.058 
FA hydroxy 20:4  C20H31O3 319.2273 1.9 -6.266 
FA 22:6 C22H31O2 327.2321 2.8 -16.919 
FA 22:5 C22H33O2 329.2477 2.7 -17.188 
FA 22:4 C22H35O2 331.2639 1.2 -20.922 
FA 22:3 C22H37O2 333.279 2.7 -17.56 
FA 22:2  C22H39O2 335.2952 1.2 -18.522 
FA 22:1 C22H41O2 337.3102 3.0 -15.492 
FA 20:4  C20H32O2Cl 339.2088 2.4 -6.08 
FA 22:0 C22H43O2 339.3258 3.2 -9.48 
FA 24:6 C24H35O2 355.2634 2.5 -16.981 
FA 24:5  C24H37O2 357.2789 2.8 -16.732 
FA 24:4 C24H39O2 359.2947 2.5 -21.34 
FA 24:3 C24H41O2 361.3103 2.5 -17.218 
FA 24:2 C24H43O2 363.3262 1.9 -17.659 
FA 24:1 C24H45O2 365.3416 2.5 -15.144 
FA 22:4  C22H36O2Cl 367.2421 -3.3 -7.137 
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FA 24:0 C24H47O2 367.3578 1.1 -6.06 
FA 25:1  C25H47O2 379.3573 2.4 -5.221 
FA methyl 24:0  C25H49O2 381.3731 1.8 -7.862 
FA 26:5 C26H41O2 385.3105 1.8 -16.964 
FA 26:4 C26H43O2 387.3260 2.3 -20.89 
FA 26:3 C26H45O2 389.3416 2.3 -16.232 
FA 26:2 C26H47O2 391.3573 2.3 -17.552 
FA 26:1 C26H49O2 393.3734 1.0 -12.345 
FA 28:2 C26H51O2 395.3884 2.8 -14.191 
FA 26:0 C26H51O2 395.3885 2.5 -6.23 
Glycerolipids         
MG 18:0/0:0 C21H40O4Cl 391.2610 2.8 -11.384 
DG 36:3/0:0 C39H70O5Cl 653.4908 1.4 -3.08 
DG 36:2/0:0 C39H72O5Cl 655.5075 -0.2 -2.453 
Glycerophosphoethanolamines         
LysoPE 16:0  C21H43NO6P 436.2821 2.8 -10.52 
LysoPE 18:0  C23H47NO7P 480.3084 2.5 -13.315 
PE 34:2 C39H73NO8P 714.5062 2.4 -6.228 
PE P-18:0/18:4  C41H73NO7P 722.5111 2.6 -18.191 
PE O-36:3 or P-36:2 C41H77NO7P 726.5417 -3.6 -5.228 
PE 36:3 C41H75NO8P 740.5217 2.6 -9.691 
PE 36:2 C41H77NO8P 742.5372 2.7 -14.611 
PE 36:1 C41H79NO8P 744.552 3.9 -10.896 
PE O-38:5 or PE P-38:4 C43H77NO7P 750.5423 2.7 -22.396 
PE 38:5 C43H75NO8P 764.5217 2.5 -11.709 
PE 38:4 C43H77NO8P 766.5374 2.3 -24.932 
PE 40:6  C45H77NO8P 790.5403 -1.4 -15.82 
PE 40:5 C45H79NO8P 792.5550 -0.1 -6.361 
PE 40:4 C45H81NO8P 794.5707 -0.3 -18.501 
Glycerophosphoglycerols         
LysoPG 18:2 C24H44O9P 507.2718 2.0 -8.529 
LysoPG 18:1 C24H46O9P 509.2876 1.8 -4.018 
LysoPG 22:6 C28H44O9P 555.2720 1.4 -7.775 
PG 16:0/18:1 C40H76O10P 747.5160 2.9 -8.047 
PG 36:4  C42H74O10P 769.5002 3.0 -12.51 
PG 18:2/18:1  C42H76O10P 771.5152 3.9 -4.627 
PG 18:1/18:1  C42H78O10P 773.5316 2.8 -5.956 
PG 38:2 C44H82O10P 801.5639 1.5 -10.651 
PG 40:8 C46H74O10P 817.5004 2.6 -6.68 
Monoacylglycerophosphates          
PA 32:0 C35H68O8P 647.4639 -2.8 -5.362 
PA 24:2 C37H68O8P 671.4641 2.4 -5.662 
PA 36:4 C39H68O8P 695.4643 2.0 -8.407 
PA 36:3 C39H70O8P 697.4804 1.4 -9.11 
PA 36:2 C39H72O8P 699.4948 3.1 -6.552 
Cardiolipins         
CL 72:8  C81H140O17P2 723.4766 -3.0 -7.731 
CL 72:7 C81H142O17P2 724.4834 4.6 -8.549 
CL 72:4 C81H148O17P2 727.5070 4.3 -4.471 
CL 74:10 C83H140O17P2 735.4758 4.1 -6.673 
CL  74:9 C83H142O17P2 736.4847 2.7 -8.388 
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CL  74:8 C83H144O17P2 737.4922 3.1 -16.348 
CL  74:7 C83H146O17P2 738.5022 0.1 -18.066 
CL  74:6 C83H148O17P2 739.5074 3.7 -16.188 
CL 79:10 C85H144O17P2 749.4924 2.8 -8.087 
CL 79:9 C85H146O17P2 750.5026 -0.4 -5.903 
CL 79:8 C85H148O17P2 751.5077 3.2 -9.615 
CL 79:7 C85H150O17P2 752.5180 0.1 -5.77 
Glycerophosphoinositols         
LysoPI 18:0 C27H52O12P 599.3189 2.2 -13.656 
LysoPI 20:4 C29H48O12P 619.2868 3.4 -7.542 
PI 36:4 C45H78O13P 857.5163 2.7 -12.731 
PI 36:3 C45H80O13P 859.5312 3.5 -8.368 
PI 36:2 C45H82O13P 861.5475 2.8 -9.857 
PI 37:4 C46H80O13P 871.5332 1.1 -7.472 
PI 38:5 C47H80O13P 883.5321 2.4 -10.395 
PI 38:4 C47H82O13P 885.5474 2.8 -17.953 
PI 38:3 C47H84O13P 887.5653 -0.2 -13.431 
PI 39:4 C48H84O13P 899.5629 2.9 -8.627 
PI 40:6 C49H82O13P 909.5480 -2.1 -10.136 
PI 40:5 C49H84O13P 911.5627 -3.1 -11.638 
PI 40:4 C49H86O13P 913.5783 3.2 -19.748 
Glycerophosphoserines      
PS 36:4 C42H73NO10P 782.4961 2.2 -6.987 
PS 36:3 C42H75NO10P 784.5119 1.9 -4.53 
PS 36:2 C42H77NO10P 786.5270 2.7 -13.616 
PS 18:0/18:1 C42H79NO10P 788.5429 2.3 -10.371 
PS 38:4  C44H77O10NP 810.5269 2.7 -21.491 
PS 38:3 C44H79NO10P 812.5416 3.8 -12.988 
PS 38:2 C44H81NO10P 814.5577 3.3 -8.516 
PS 39:4 C45H79NO10P 824.5432 1.8 -9.394 
PS 39:3 C45H81NO10P 826.5628 -2.9 -4.376 
PS 40:6 C46H77O10NP 834.5269 2.6 -12.156 
PS 40:4 C46H81O10NP 838.5578 3.1 -20.635 
PS 22:6/19:0 C46H81O10NP 848.5439 0.9 -10.301 
PS 41:4 C47H83O10NP 852.5732 3.3 -7.748 
 
Table 10. Mice samples – Control - highFABP4 – 125 m/z values  
 
MICE SAMPLES – siFABP4 - LOW FABP4 EXPRESSION 
Attribution  Molecular Formula  
Detected 
m/z  
Mass error 
(ppm) 
SAM 
Score 
Metabolites     
Succinate C4H5O4 117.0193 0.6 14.447 
Glutathione C10H16N3O6S 306.0756 -2.9 2.372 
Methymycin C25H43NO7Cl 504.2720 -2.8 3.565 
Glycerolipids     
DG 32:1/0:0 C35H66O5Cl 601.4593 1.8 5.518 
DG 34:2/0:0 C37H68O5Cl 627.4747 -2.2 4.196 
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DG 34:1/0:0 C37H70O5Cl 629.4914 -0.5 5.772 
DG 36:4/0:0 C39H68O5Cl 651.4748 2.0 1.339 
DG 36:1/0:0 C39H74O5Cl 657.5229 0.2 3.089 
DG 38:6/0:0 C41H68O5Cl 675.4751 1.5 4.087 
DG 38:5/0:0 C41H70O5Cl 677.4903 2.1 5.15 
DG 38:4/0:0 C41H72O5Cl 679.5057 2.5 3.376 
DG 40:8/0:0 C43H68O5Cl 699.4742 2.7 4.638 
DG 40:7/0:0 C43H70O5Cl 701.4901 2.3 3.189 
DG 40:7/0:0 C43H72O5Cl 703.5063 1.6 3.147 
Glycerophosphoethanolamines      
PE 18:1 C24H45NO8P 506.2876 2.4 2.363 
PE 36:2 C41H77NO8P 742.5378 1.9 2.007 
PE 38:6 C43H73NO8P 762.5040 5.1 4.499 
PE 37:1 C42H82NO8PCl 794.5444 3.5 2.379 
PE 38:6 C43H73NO8P 762.5040 5.1 4.499 
PE 39:2 C44H84NO8PCl 820.5595 4.1 2.855 
Glycerophosphoglycerol
s        
PG 22:1 C38H72O10P 719.4857 1.7 2.984 
PG 34:1 C40H72O10P 743.4850 2.6 2.738 
PG P-26:2 or PG O-36:3 C42H78O9P 757.5385 0.5 8.120 
PG P-36:1 or PG O-36:2 C42H80O9P 759.5526 2.5 3.118 
PG 18:0/18:1 C42H80O10P 775.5482 1.7 4.647 
PG 18:0/18:0 C42H82O10P 777.5651 0.3 5.331 
PG 38:7 C44H72O10P 791.4848 2.7 2.043 
PG 38:5 C44H76O10P 795.5145 4.7 2.059 
PG 42:9 C48H76O10P 843.5146 4.3 5.532 
Ceramides        
Cer d32:1 C32H63NO3Cl 544.4492 1.8 2.891 
Cer 34:2 C34H65NO3Cl 570.4644 2.5 5.907 
Cer 34:1 C34H67NO3Cl 572.4802 2.3 5.537 
Cer d18/16:0 C34H69NO3Cl 574.4960 1.9 3.892 
Cer m18:1/22:0 C40H79NO2Cl 640.5790 2.3 3.255 
Cer d40:2 C40H77NO3Cl 654.5585 1.8 5.066 
Cer d40:2 C40H77NO3Cl 656.5741 2.0 2.583 
Cer m42:1 C42H83NO2Cl 668.6107 1.6 6.489 
Cer d42:1 C42H83NO3Cl 684.6071 0.6 9.328 
Cer d42:0 C42H85NO3Cl 686.6207 2.3 6.922 
Cer m44:1 C44H87NO2Cl 696.6413 2.6 5.418 
Cer d18:1/26:1 C44H85NO3Cl 710.6239 2.3 3.455 
Cer d18:1/26:0 C44H87NO3Cl 712.6379 0.1 7.647 
GlcCer d34:2 C50H95NO8Cl 872.6757 -0.6 4.767 
GlcCer d34:1 C50H97NO8Cl 874.6869 4.5 6.519 
Cardiolipins        
CL 70:7 C79H138O17P2 710.4689 3.0 4.073 
CL 70:6 C79H140O17P2 711.4755 4.6 2.794 
CL 74:10 C83H140O17P2 735.4779 1.2 0.599 
CL 74:9 C83H142O17P2 736.4852 2.0 1.58 
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Glycerophosphoinositol
s        
PI O-31:1 or PI P-31:0 C40H77O12PCl 815.4856 -1.1 2.002 
Glycerophosphoserines        
PS P-33:0 C39H75NO9P 732.5171 1.9 5.018 
PS P-36:2 or PS O-36:3 C42H77NO9P 770.5324 2.2 3.814 
PS O-36:2 or PS P-36:1 C42H79NO9P 772.5490 1.0 2.084 
PS 18:0/18:1 C42H79NO10P 788.5466 -2.4 4.731 
PS O-39:0 C45H89NO9P  818.6258 2.7 1.992 
PS 40:2 C46H85O10NP 842.5894 2.7 2.74 
PS 40:1 C46H87O10NP 844.6056 2.0 3.798 
PS O-41:0 C47H93O9NP 846.6582 1.3 9.73 
PS 42:2 C48H89O10NP 870.6213 2.0 4.253 
PS 42:1 C48H91O10NP 872.6357 3.3 3.518 
 
Table 11 Mice samples – siFABP4 - lowFABP4 – 59 m/z values 
 
AGREEMENTS WITH HUMAN - CONTROL - HIGH FABP4 EXPRESSION 
Attribution  Molecular Formula  
Detected 
m/z  
Mass error 
(ppm) 
SAM 
Score 
Metabolites      
Taurine  C2H6NO3S 124.0073 0.8 -5.756 
Xanthine C5H3O2N4 151.026 -0.7 -6.716 
Fatty Acids     
FA 18:3 C18H29O2 277.2167 -2.2 -14.723 
FA 18:2 C18H31O2 279.2324 -2.1 -22.826 
FA 18:1 C18H33O2 281.248 -2.1 -22.745 
FA 18:0 C18H35O2 283.2636 -2.1 -21.869 
FA 19:0 C19H37O2 297.2792 -2.4 -16.768 
FA 20:5 C20H29O2 301.2165 2.7 -7.552 
FA 20:4 C20H31O2 303.2322 2.6 -22.184 
FA 18:2  C18H32O2Cl 315.2087 2.9 -6.647 
FA 18:1  C18H34O2Cl 317.2245 2.5 -6.058 
FA hydroxy 20:4  C20H31O3 319.2273 1.9 -6.266 
FA 22:6 C22H31O2 327.2321 2.8 -16.919 
FA 22:5 C22H33O2 329.2477 2.7 -17.188 
FA 22:4 C22H35O2 331.2639 1.2 -20.922 
FA 22:3 C22H37O2 333.2790 2.7 -17.56 
FA 20:4 C20H32O2Cl 339.2088 2.4 -6.08 
FA 24:5  C24H37O2 357.2789 2.8 -16.732 
FA 24:4 C24H39O2 359.2947 2.5 -21.34 
FA 22:4 C22H36O2Cl 367.2421 -3.3 -7.137 
Glycerolipids         
MG 18:0/0:0 C21H40O4Cl 391.2610 2.8 -11.384 
DG 36:3/0:0 C39H70O5Cl 653.4908 1.4 -3.08 
DG 36:2/0:0 C39H72O5Cl 655.5075 -0.2 -2.453 
Glycerophosphoethanolamines       
LysoPE 16:0  C21H43NO6P 436.2821 2.8 -10.52 
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LysoPE 18:0  C23H47NO7P 480.3084 2.5 -13.315 
PE P-18:0/18:4  C41H73NO7P 722.5111 2.6 -18.191 
PE O-38:5 or PE P-38:4 C43H77NO7P 750.5423 2.7 -22.396 
PE 38:5 C43H75NO8P 764.5217 2.5 -11.709 
PE 40:5 C45H79NO8P 792.5550 -0.1 -6.361 
PE 40:4 C45H81NO8P 794.5707 -0.3 -18.501 
Glycerophosphoglycerol
s         
LysoPG 18:2 C24H44O9P 507.2718 2.0 -8.529 
LysoPG 18:1 C24H46O9P 509.2876 1.8 -4.018 
LysoPG 22:6 C28H44O9P 555.2720 1.4 -7.775 
PG 16:0/18:1 C40H76O10P 747.5160 2.9 -8.047 
PG 36:4  C42H74O10P 769.5002 3.0 -12.51 
PG 18:2/18:1  C42H76O10P 771.5152 3.9 -4.627 
PG 18:1/18:1  C42H78O10P 773.5316 2.8 -5.956 
PG 40:8 C46H74O10P 817.5004 2.6 -6.68 
Cardiolipins         
CL 72:4 C81H148O17P2 727.5070 4.3 -4.471 
Glycerophosphoinositol
s         
LysoPI 18:0 C27H52O12P 599.3189 2.2 -13.656 
LysoPI 20:4 C29H48O12P 619.2868 3.4 -7.542 
PI 37:4 C46H80O13P 871.5332 1.1 -7.472 
PI 38:5 C47H80O13P 883.5321 2.4 -10.395 
PI 38:4 C47H82O13P 885.5474 2.8 -17.953 
PI 38:3 C47H84O13P 887.5653 -0.2 -13.431 
PI 40:6 C49H82O13P 909.5480 -2.1 -10.136 
PI 40:4 C49H86O13P 913.5783 3.2 -19.748 
Glycerophosphoserines         
PS 36:3 C42H75NO10P 784.5119 1.9 -4.53 
PS 38:4  C44H77O10NP 810.5269 2.7 -21.491 
PS 39:4 C45H79NO10P 824.5432 1.8 -9.394 
 
Table 12. Same species for human and mice samples - highFABP4 – 50 m/z values  
 
AGREEMENTS WITH HUMAN - siFABP4 - LOW FABP4 EXPRESSION 
Attribution  Molecular Formula  Detected m/z  Mass error (ppm) SAM Score 
Metabolites          
Succinate C4H5O4 117.0193 0.6 14.447 
Glutathione  C10H16N3O6S 306.0756 -2.9 2.372 
Glycerophosphoethanolamines       
PE 18:1 C24H45NO8P 506.2876 2.4 2.363 
PE 36:2 C41H77NO8P 742.5378 1.9 2.007 
PE 38:6 C43H73NO8P 762.5040 5.1 4.499 
Glycerophosphoglycerols       
PG 18:0/18:1 C42H80O10P 775.5482 1.7 4.647 
PG 18:0/18:0 C42H82O10P 777.5651 0.3 5.331 
PG 42:7 C48H80O10P 847.5431 7.6 6.468 
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Ceramides       
Cer d18/16:0 C34H69NO3Cl 574.4960 1.9 3.892 
Cer m18:1/22:0 C40H79NO2Cl 640.5790 2.3 3.255 
Cer m42:1 C42H83NO2Cl 668.6107 1.6 6.489 
Cer d42:1 C42H83NO3Cl 684.6071 0.6 9.328 
Cer d42:0 C42H85NO3Cl 686.6207 2.3 6.922 
Cer d18:1/26:1 C44H85NO3Cl 710.6239 2.3 3.455 
Cer d18:1/26:0 C44H87NO3Cl 712.6379 0.1 7.647 
Cardiolipins         
CL 70:7 C79H138O17P2 710.4689 3.0 4.073 
CL 70:6 C79H140O17P2 711.4755 4.6 2.794 
CL 74:10 C83H140O17P2 735.4779 1.2 0.599 
CL 74:9 C83H142O17P2 736.4852 2.0 1.58 
Glycerophosphoserines     
PS P-36:2 or PS O-36:3 C42H77NO9P 770.5324 2.2 3.814 
PS O-36:2 or PS P-36:1 C42H79NO9P 772.5490 1.0 2.084 
PS 18:0/18:1 C42H79NO10P 788.5466 -2.4 4.731 
PS 40:2 C46H85O10NP 842.5894 2.7 2.74 
PS 40:1 C46H87O10NP 844.6056 2.0 3.798 
PS 42:2  C48H89O10NP 870.6213 2.0 4.253 
PS 42:1 C48H91O10NP 872.6357 3.3 3.518 
 
Table 13. Same species for human and mice samples - lowFABP4 – 26 m/z values  
  
115 
 
Effect of FABP4 expression on overall and progression-free survival 
We queried Tothill ovarian cancer patient data set to investigate the association 
between FABP4 and overall and progression-free survival. The data were available 
for 2 probesets for FABP4. Using multi-variate analysis, we observed that there was 
a significant correlation between high FABP4 expression and overall survival (Figure 
29 a) and with progression-free survival (Figure 29 b) for both the probe-sets. For the 
univariate analysis as well, high FABP4 correlated with poor overall (Figure 29 c) and 
progression-free survival (Figure 29 d). 
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Figure 29 (a) Multivariate analysis of FABP4 (for two probes) for overall survival using 
Tothill data set. (b) Multivariate analysis of FABP4 (for two probes) for progression-
free survival using Tothill data set (c) Univariate analysis for FABP4 using Tothill data 
set for overall survival (d) Univariate analysis for FABP4 using Tothill data set for 
progression-free survivalFABP4 in uterine cancer 
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Chapter 8: FABP4 as a predictor of residual disease in uterine cancer   
Having established the importance of FABP4 in residual disease of ovarian 
cancer, we decided to investigate if it can be used as a predictor for other cancer types 
as well. We selected uterine cancer since the standard of care for this cancer is similar 
to that of ovarian cancer (Primary debulking surgery followed by adjuvant 
chemotherapy). We initially checked FABP4 expression in uterine cancer cell lines 
and noticed that the expression is considerably low (Figure 30 a). However, 
sometimes tumor micro-environment can induce certain gene expressions. We hence 
decided to check expression of FABP4 in tumor samples collected from uterine cancer 
mouse models. We checked the expression on tumor collected from SKUT2, HEC1a, 
ISHIKAWA and SPEC2 mouse models and compared it to the HeyA8 MDR mouse 
model (Positive control) staining. We noticed that uterine tumor tissues do express 
FABP4 in vivo (Figure 30 b). The next step was to investigate patient data base and 
explore the association between FABP4 expression and incidences of residual 
disease. We analyzed TCGA data and segregated the samples as endometrioid or 
serous. The samples were then divided into residual disease (RD) or no residual 
disease (R0) groups. There was however, no significant correlation between FABP4 
expression and residual disease incidences in both of these groups (Figure 30 c and 
d). We thus concluded that relation between FABP4 and RD is unique for ovarian 
cancer.  
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Figure 30 (a) Expression of FABP4 in a uterine cancer cell line panel. (b) 
Immunohistochemical staining showing expression of FABP4 in in vivo mouse models 
of uterine cancer. (c, d) Relation between FABP4 and residual disease status in (c) 
endometrioid and (d) serous subtypes of uterine cancer, R0- No residual disease, RD-
Residual disease (TCGA patient database). 
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Chapter 9: Therapeutic options to target FABP4 in patients 
Our results thus far recognize FABP4 as a promising therapeutic target for 
ovarian cancer patients. Our next step, therefore, was to search for clinically approved 
drugs that can target FABP4. In a recent study, tamoxifen, a selective estrogen 
modulator, has been shown to inhibit FABP4 in macrophages [92]. We decided to 
check if it can suppress FABP4 in ovarian cancer cells. We used physiologically 
relevant concentrations of tamoxifen and checked its effects on FABP4 expression. 
We treated HeyA8 MDR cells with various concentrations of tamoxifen, for different 
time intervals. At a concentration of 3.5 uM, after 24 hours, tamoxifen inhibited FABP4 
expression by more than 50% (p<0.0.5) (Figure 31 a). We then decided to check if 
this inhibition was functionally relevant. We first conducted free fatty acid uptake 
assay. Since FABP4 plays a key role in uptake and metabolism of fatty acids, this 
assay reflects if inhibition of FABP4 was sufficient enough to affect its functions. 
Tamoxifen inhibition of FABP4 significantly impaired the ability of cancer cells to 
uptake free fatty acids as shown in Figure 30 b (p<0.01). We also checked if we see 
any effect on metastasis related pathways. We noticed that inhibition of FABP4 by 
Tamoxifen suppressed migratory ability by cancer cells significantly p< 0.05 (Figure 
30 c). Tamoxifen is thus a potential candidate for FABP4 inhibition in ovarian cancer.  
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Figure 31 (a) Effect of tamoxifen treatment on the expression of FABP4 in HeyA8 
MDR cells. *p<0.05. (b) Effect of tamoxifen treatment on the ability of cancer cells to 
take up free fatty acids (HeyA8 MDR cells). **p<0.01. (c) Change in the migratory 
potential of cancer cells after tamoxifen treatment (HeyA8 MDR cells). *p<0.05.  
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Chapter 10: Discussion 
Systematically combining clinical data, experimental models and 
bioinformatics, we explored the underlying biology of residual disease in ovarian 
cancer. Using publicly available datasets we have shown that high expression of 
FABP4 and ADH1B can predict increased likelihood of residual disease in ovarian 
cancer patients. The results were also validated by additional patient cohorts taken 
from two cancer institutes. If confirmed by additional external validations, this study 
has potential applications in the clinical settings for personalized treatment 
approaches. If a patient has high likelihood of having residual disease after the 
debulking surgery, it would be more beneficial to give her neoadjuvant chemotherapy 
first. It might increase chances of achieving complete cytoreduction at interval 
debulking thus improving patient prognosis. Avoiding unnecessary surgeries will also 
reduce the surgery-associated morbidities in patients. Thus, it is crucial to personalize 
the treatment options (NACT or PDS) based the residual disease predictions for a 
given patient.  
Previous studies have employed CT scans or CA-125 levels for prediction of 
suboptimal cytoreduction, but they do have certain limitations [20, 29, 30]. Most of the 
studies used old classifications of ‘optimal’ and ‘suboptimal’ cytoreduction. Recent 
studies have established the importance of R0 resection making the old classification 
system inadequate to assess prognostic impact. Thus, some of the earlier studies may 
not be valid any longer since the markers were not particularly used to study R0/RD 
status. Many CT scan based studies also lack external validity [13, 34] . 
122 
 
Recent studies have explored the gene signatures of residual tumors of ovarian 
cancer. A study of 213 ovarian cancer patients showed that tumor samples 
simultaneously overexpressing GLUT-1 and Ki-67 were more likely to get suboptimally 
cytoreduced than other tumor samples [93]. Another study with 44 advanced serous 
ovarian cancers identified 120 genes that were differentially expressed between 
optimally and suboptimally cytoreduced tumors. A predictive model consisting of 32 
genes was able to predict optimal or suboptimal debulking with 72.7% accuracy [94]. 
Several of the genes found to be predictors of suboptimal disease were linked with 
increased metastasis in ovarian cancer. The study however did not validate in internal 
cross-validation. Other genes including IGF1R, VEGF-C, SRA1, TGFβ1, CAR3/7, 
CAR4/7, RNAse III Dicer have been found to be associated with suboptimal debulking 
of ovarian cancer [95-100]. Certain proteins such as cyclin E, c-erb-B-2, Twist, p63α, 
ERCC1, AEG-1, P130cas have also been found to be correlated with increased 
likelihood of suboptimal cytoreduction [101-107]. Immunoprofiling of 232 ovarian 
tumors have shown increased number of T-regulatory cells (CD4+CD25+ T cells) in 
suboptimally resected patient samples compared to the samples from optimally 
debulked patients [108]. Epigenetic modifications have also been linked with surgical 
outcome. HOXA11 methylation levels have been found to be significantly different 
between <2cm residual disease and > 2cm residual disease [109]. A large study 
based on meta-analysis of 1525 samples of primary, late stage high-grade serous 
ovarian tumors has revealed a gene signature that is differentially expressed in 
optimally suboptimally cytoreduced tumors. Validations studies using qRT-PCR and 
immunohistochemical staining have revealed POSTN, CXCL14, phosphorylated 
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Smad2/3 as independent predictors of debulking status. The model based on these 
three proteins was able to classify high and low risk samples with 92.8% accuracy. 
Pathways analysis of this gene signature revealed activation of TGF-β1/Smad 
signaling pathway, RTK/Ras/MAPK/Erg-1, AMPK/Erg-1 and Hedgehog/Gli signaling 
in tumors taken from suboptimally cytoreduced patients [110]. Although these studies 
have several limitations; such as small number of samples, lack of independent 
validation, inclusion of heterogeneous tumor types, grades and varying definitions of 
optimal, suboptimal instead of R0, RD cases etc.; they indicate that tumor biology 
plays a crucial role in determining the surgical outcome of ovarian cancer patients.  
In the light of the limitations of other studies, our study to identify molecular 
predictors is unique for the following reasons: 1) We used R0 and RD as our clinical 
endpoints. Various studies have shown that there is a larger difference in overall 
survival between R0 and RD patients compared to the difference between optimal and 
suboprimal surgeries. Moreover, the definition of R0 is consistent across all the 
centers contrary to the definitions of optimal cytoreduction which vary. 2) The assay if 
approved will be used for patients who had not received any prior chemotherapy. 
Hence, we only focused on primary tumors of high grade serous ovarian cancer from 
patients who had not received any neoadjuvant chemotherapy or surgery. 3) To avoid 
batch effects, we used two different datasets, confirmed the results in a separate 
patient dataset and validated it experimentally using another separate patient cohort. 
4) To make the test clinically feasible, we restricted the selection to a small number of 
predictors. 5) The odds ratio for prediction by CA-125 levels are lower than our 
prediction of residual disease using FABP4 expression [24, 111]. 
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However, compared to the clinical data such as CT-scans, CA-125 levels or 
laparoscopic measurements; information about molecular predictors would be less 
readily available to the surgeons. Hence, predictions using molecular biomarkers 
would probably be combined with laparoscopic assessment to predict RD status of a 
patient.  
Little is known about the biology of residual disease in ovarian cancer. This 
study not only delineates the downstream signaling of FABP4 leading to residual 
disease, it also investigates the regulation of FABP4. Hypoxia has been known to 
promote tumor progression however, its exact role in the pattern of metastasis was 
not known. We show that hypoxia suppresses miR-409-3p thus removing FABP4 
inhibition which leads to FABP4 upregulation ultimately leading to residual disease. 
miR-409-3p has also been studied in various types of cancers such as gastric, 
colorectal, breast, prostate, glioblastoma, fibrosarcoma and osteosarcoma. In 
glioblastoma, miR-409-3p has been shown to regulate O6-methylguanine-DNA 
methyltransferase (MGMT) [112]. It also suppresses glioma cell proliferation and 
invasion by targeting HMGN5 [113]. In colon cancer, miR-409-3p can suppress Beclin-
1 and thus inhibits chemotherapy induced autophagy and sensitizes the cancer cells 
to chemotherapy. Its expression is also lower in colorectal cancer tissues compared 
to the adjacent non-tumor tissues. In addition to Beclin, NLK and GAB1 have been 
shown to be targets of miR-409-3p [114-116]. In fibrosarcoma cell line HT1080; miR-
409-3p suppresses tumor growth, vascularization and metastasis by targeting 
angiogenesis (ANG) [117]. miR-409-3p has been extensively studied in breast cancer. 
It has been shown to suppress proliferation, migration and invasion of breast cancer 
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cell lines and shown to inhibit tumor progression possibly by downregulating its target 
genes such as AKT and ZEB1 [118, 119]. Patient sample analyses have also shown 
that its expression is low in tumor tissues compared to normal breast tissue 
specimens. Moreover, it has also been suggested as a detection and prognostic 
marker of breast cancer since its plasma levels are found to be lower in cancer 
patients compared to the normal controls [120, 121]. The importance of miR-409-3p 
as a tumor suppressor has also been studied in gastric cancer. It is significantly 
downregulated in gastric cancer cell lines and tumor tissues compared to non-
tumorous samples. Moreover, its expression is lower in patients with lymph node 
metastasis compared to the patients without lymph node metastasis [122]. In gastric 
cancer, radixin and PHF10 are shown to be the targets of mir-409-3p [122, 123] 
whereas in osteosarcoma it inhibits metastasis and tumor progression by targeting 
CTNND1 [124]. In addition, it also acts as a tumor suppressor in lung adenosarcoma 
and bladder cancer by targeting c-Met [125]. While it acts as a tumor suppressor 
miRNA in glioblastoma, osteosarcoma, fibrosarcoma, lung, breast, gastric and colon 
cancers, it is known to promote tumor progression in prostate cancer. Higher 
expression of miR-409-3p has been observed in prostate cancer cell lines and tissues 
than the normal controls. It increases expression of EMT and stemness markers in 
cancer cells and. Delivery of miR-409-3p/5p induced tumors in mice in vivo. 
Conversely inhibition of miR-409-5p led to reduced metastasis and improved survival 
[126, 127]. The role of miR-409-3p in ovarian cancer has not been studied yet and our 
study describes its role in regulation of FABP4 and residual disease of ovarian cancer. 
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 FABP4 has been shown to be present in adipocytes, macrophages, 
endothelial cells as well as in dendritic cells. In these cell types as well, it is known to 
promote tumor progression by increasing angiogenesis, inflammation or by providing 
energy from adipocytes to the cancer cells. Our selection of primary tumors for the 
initial biomarker discovery made sure that the data mainly came from tumor cells than 
stromal cells. Our in vitro studies focused on how changes in FABP4 expression in 
cancer cells affects their metastatic potential. In our in vivo studies as well, we utilized 
DOPC nanoliposomes which are known to be specifically uptaken by cancer cell. Thus 
inhibition of tumor progression can be attributed to the inhibition of FABP4 in cancer 
cells than stromal cells. Further, we used DESI-MS imaging technique to study the 
metabolic changes associated with FABP4 and we extracted data specifically from 
cancer cell compartment of the tumor tissues. None of the previous studies used such 
sophisticated techniques to delineate the spatial information about the functions of 
FABP4. We here present evidences that FABP4 specifically present in cancer cells 
can regulate multiple proteins and metabolites to increase infiltrative behavior and 
metastatic potential of cancer cells.  We thus show that FABP4 present in cancer cells 
is responsible for residual disease while stromal FABP4 might play a secondary role 
in this pathway.  
DESI-MS imaging showed that lipidomic profiles of R0 and RD patients differ 
significantly. Mice data also revealed that FABP4 manipulation had significant effects 
on the metabolites present in cancer cells. Higher unsaturation and oxidation of fatty 
acids and lysophospholipids were observed in higher relative abundance in samples 
with high FABP4 expression. Studies have suggested that unsaturated fatty acids can 
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activate the beta catenin pathway, downregulate PTEN or increase cancer cell 
adhesion and thus play a key role in pathways leading to tumor progression by [128-
130]. Fatty acid oxidation has been linked with increased metastasis in breast and 
ovarian cancer models [52, 131].  Lysophospholipids are considered potential 
biomarkers for ovarian cancer. They have also been known to increase cancer cell 
migration thus helping tumor progression [132, 133]. High expression of FABP4 can 
thus regulate various metabolites and protein pathways that can lead to aggressive 
disease. 
Future directions 
Our study has shown FABP4 and ADH1B as promising molecular biomarkers 
for prediction of residual disease. However, in order to for these markers to be 
included in the clinical settings, the study needs external validation and development 
of CLIA (Clinical Laboratory Improvement Amendments)-compliant assay to assess 
FABP4 or ADH1B expression. A prospective trial analyzing FABP4 expression prior 
to triaging and comparing it with the surgical outcome of patients will be a great step 
forward in establishing the specificity and sensitivity of these markers. Our study used 
primary ovarian tumor samples to check FABP4 expression and we showed that 
expression of FABP4 in omental tissue is drastically different than its levels in ovarian 
tissues. A comprehensive study analyzing FABP4 expression in various metastatic 
tissues can further indicate whether similar results can be obtained using metastatic 
nodules. On a similar note, serum levels of FABP4 and ADH1B can also be compared 
between R0 and RD patients. If similar results can be obtained using serum samples, 
the non-invasive approach will make the study more applicable in clinics.  
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A recent study elucidating the role of stromal cell gene signature in residual 
disease biology is of particular interest [134]. It will be interesting and informative to 
study the interaction between FABP4 present in cancer cells and these genes present 
in stromal cells, and how this interplay might play a role in residual disease 
occurrence.  
Our DESI-MS data reveal many metabolites relevant for residual disease. The 
data thus lay foundation for future studies which can focus in depth on these 
metabolites and the pathways they regulate. Understanding the metabolic 
determinants of ovarian cancer growth and of leaving residual disease will further 
elucidate underlying mechanisms and open avenues for the development of 
therapeutic options targeting these moieties. 
Therapeutic strategies using siRNA and miRNAs have proven themselves to 
be attractive treatment options for a variety of diseases. In cancer therapeutics, where 
there are several undrggable targets, these miRNA and siRNA based options are of 
particular advantage. However, there are challenges in making them clinical feasible. 
Mir-34 is one of the very few miRNAs that have entered the clinical trials. Studies of 
mir-200, miR-192 and mir-630 have proven the potential of miRNA in cancer 
therapeutics [82, 135, 136]. Several siRNAs therapies including EphA2 siRNA, ELK1 
siRNA, EZH2 siRNA have been able to inhibit tumor progression [137, 138]. Few 
studies have been successful in devising delivery vehicles to carry miRNAs and 
siRNAs. The DOPC nanoliposomes used in our study have shown promising results 
in many prior preclinical studies [136-139]. The liposomes are currently being tested 
in Phase 1 clinical trials for delivery of EphA2 siRNAs (NCT01591356). Our study 
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utilizing DOPC nanoliposomes encapsulating FABP4 siRNA and miR-409-3p mimic 
thus provides further evidence that siRNA and miRNA based treatment options have 
potential as cancer therapeutics, specifically for the management of metastatic 
disease.  
Significance and translational relevance  
Residual disease following primary debulking has been associated with poor 
prognosis of cancer patients. Patients with high risk of residual disease should ideally 
be treated with neoadjuvant chemotherapy to increase the chances of R0 resection at 
interval debulking surgery and avoid unnecessary morbidities associated with 
cytoreductive surgeries. In this study, we developed molecular biomarkers that can 
predict the likelihood of residual disease in ovarian cancer patients. Use of these 
biomarkers can help clinicians in triaging patients to personalized treatment option. 
Patients with high expression of FABP4 and ADH1B can be at high risk of residual 
disease, hence will be ideal candidates for neoadjuvant chemotherapy instead of 
unwarranted aggressive primary surgery. This approach will not only increase overall 
survival but can also improve quality of life of ovarian cancer patients.  
Little is known about the underlying biology of residual disease. Our study uses 
various in vitro and in vivo techniques to investigate the pathways that lead to residual 
disease and demonstrates the crucial role FABP4 plays in promoting invasiveness 
and infiltration of cancer cells. Moreover, ours is the first study to use in vivo mouse 
models to study this clinically observed phenomenon. Since the exact replication of 
aggressive cytoreduction and assessment of residual disease is not possible in mice; 
we devised a modified version of a clinically validated method to predict the likelihood 
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of leaving residual disease in in vivo experiments. We hope that this new modified 
scoring systems proves useful in initiating more in vivo experiments to study yet 
unknown aspects of residual disease pathophysiology.   
We also explore the upstream regulatory mechanisms of FABP4 and identified 
hypoxia as a major tumor micro-environmental factor regulating FABP4. We further 
show that miR-409-3p directly targets FABP4 and in turn is regulated by hypoxia. We 
thus provide several lines of evidence that hypoxia-miR-409-3p-FABP4 is the major 
axis regulating residual disease in ovarian cancer. Downstream of FABP4, we 
investigated protein and lipid pathways regulated by FABP4. Although studies have 
focused on the metabolomics of ovarian cancer [56-58]; they don’t identify specific 
tumor compartments where the metabolic changes occur. We thus used DESI-MS 
imaging technique to get the spatial information of the metabolites. The use of DESI-
MS technique was mainly considered in identifying tumor margins in surgical resection 
or in disease diagnosis [65]. We successfully applied this technique 1) To identify 
cancer cell-specific metabolomics associated with FABP4 expression in ovarian 
cancer patients 2) To identify metabolomics changes occurring in the cancer cell 
compartment after inhibiting FABP4 expression in vivo. Identifying the exact location 
of metabolic changes is crucial, not only in understanding how a gene’s functions 
influence and shape the cancer biology but it will also help in future therapeutic 
development.  
We identify FABP4 and miR-409-3p as promising therapeutic targets in ovarian 
cancer and using DOPC nanoliposomes containing targeted siRNA and miRNA 
molecules, we establish their importance in inhibiting tumor progression. We also 
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tested a clinically approved drug to target FABP4. Tamoxifen has mainly been used 
in the treatment of breast cancer[140].Some clinical trials have used tamoxifen for 
ovarian cancer treatment, but the results of those trials were mixed[141-143]. 
However, it is important to note that those patients had advanced stage ovarian cancer 
and no specific biomarker was used to select patients who would respond to tamoxifen 
treatment. Our preliminary experiments suggest that tamoxifen can suppress 
expression and functions of FABP4 and can inhibit tumor progression. Future studies 
are essential to establish tamoxifen as a part of ovarian cancer management, but our 
study lays the foundation for repurposing tamoxifen, a clinically approved drug for 
additional usage and also proposes a biomarker (FABP4) to select patients who will 
benefit the most with tamoxifen treatment.  
Figure 32 gives a summary of results of our study. 
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Figure 32 Summary model 
We, thus, provide an important conceptual advance in understanding the 
causal biology of residual disease, a molecular biomarker based method to predict the 
RD status and new therapeutic avenues for ovarian cancer treatment.  
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